# SCIENTIFIC **REPORTS**

Received: 16 December 2016 Accepted: 4 July 2017 Published online: 21 August 2017

## **OPEN** Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies

Junjun Wang<sup>1,2</sup>, Qingyun Liu<sup>1</sup>, Shuai Yuan<sup>1</sup>, Weijia Xie<sup>1</sup>, Yuan Liu<sup>1</sup>, Ying Xiang<sup>1,2</sup>, Na Wu<sup>1,2</sup>, Long Wu<sup>1,2</sup>, Xiangyu Ma<sup>1,2</sup>, Tongjian Cai<sup>1,2</sup>, Yao Zhang<sup>1,2</sup>, Zhifu Sun<sup>3</sup> & Yafei Li<sup>1,2</sup>

More than 1000 candidate-gene association studies on genetic susceptibility to lung cancer have been published over the last two decades but with few consensuses for the likely culprits. We conducted a comprehensive review, meta-analysis and evidence strength evaluation of published candidate-gene association studies in lung cancer up to November 1, 2015. The epidemiological credibility of cumulative evidence was assessed using the Venice criteria. A total of 1018 publications with 2910 genetic variants in 754 different genes or chromosomal loci were eligible for inclusion. Main meta-analyses were performed on 246 variants in 138 different genes. Twenty-two variants from 21 genes (APEX1 rs1130409 and rs1760944, ATM rs664677, AXIN2 rs2240308, CHRNA3 rs6495309, CHRNA5 rs16969968, CLPTM1L rs402710, CXCR2 rs1126579, CYP1A1 rs4646903, CYP2E1 rs6413432, ERCC1 rs11615, ERCC2 rs13181, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, MIR196A2 rs11614913, OGG1 rs1052133, PON1 rs662, REV3L rs462779, SOD2 rs4880, TERT rs2736098, and TP53 rs1042522) showed significant associations with lung cancer susceptibility with strong cumulative epidemiological evidence. No significant associations with lung cancer risk were found for other 150 variants in 98 genes; however, seven variants demonstrated strong cumulative evidence. Our findings provided the most updated summary of genetic risk effects on lung cancer and would help inform future research direction.

Lung cancer is the most common cancer and the leading cause of cancer-related mortality around the world<sup>1</sup>. While smoking is the leading cause of lung cancer, genetics plays an important role as less than 20% of smokers develop this deadly disease in their lifetime<sup>2</sup> and non-smokers with a family history of cancer have an increased risk of lung cancer<sup>3</sup>.

Genetic variants influencing lung-cancer risk fall into three categories: rare high-risk variants (prevalence of 1% or less), moderate-risk variants (prevalence of not more than 5%), and common low-risk variants (prevalence of more than 5%). Family-based linkage studies is most appropriate for high risk variants with high penetrance but more costly to conduct as lung cancer is a common disease and multiple occurrences of lung cancer in a family are less common. To date, the most concrete linkage and fine mapping studies reveal a lung-cancer susceptibility locus at 6q23-25 and RGS17 as a possible culprit gene<sup>4-6</sup>.

Based on the "common disease and common variant" hypothesis, genome-wide association studies (GWAS) provide a powerful tool for investigating the genetic association of a complex disease<sup>7</sup>. Over the past ten years, common genetic variations at 5p15.33 (TERT/CLPTM1L), 6p21.33 (BAT3/MSH5) and 15q25.1 (CHRNA5/ CHRNA3/CHRNB4) are identified to modify the lung cancer susceptibility in GWAS<sup>8-13</sup> and GWAS-based

<sup>1</sup>Department of Epidemiology, College of Preventive Medicine, Third Military Medical University, Chongqing, People's Republic of China. <sup>2</sup>Center for Clinical Epidemiology and Evidence-Based Medicine, Third Military Medical University, Chongging, People's Republic of China. <sup>3</sup>Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Junjun Wang, Qingyun Liu, Shuai Yuan and Weijia Xie contributed equally to this work. Correspondence and requests for materials should be addressed to Y.Li (email: liyafei2008@hotmail.com)

meta-analyses<sup>14, 15</sup> (eg, *TERT* rs2736100, *CHRNA3* rs8042374, *APOM* rs3117582, *MSH5* rs3131379, and *GTF2H4* rs114596632). However, these only explain less than 10% of the risk contribution to lung cancer<sup>16</sup>.

Candidate-gene approaches were the mainstay of genetic association studies before the GWAS era. They are relatively cost-effective and easy to perform. Over 1,000 such studies on the lung cancer susceptibility have been published for the past 25 years. However, there are a number of conflicting reports and it is very challenging to find reliable associations from these highly diverse studies. As a method for systematically integrating data from multiple studies to develop a single conclusion with greater statistical power, meta-analysis is a good way to deal with the diverse and fragmented studies. Although some meta-analyses have been performed on lung cancer, most are limited to investigating a single genetic variant, several variants in a gene, or several variants across a pathway. The recent systematic meta-analyses push the limit to all available genetic association studies in a specific disease and help to achieve a comprehensive view to the genetic contributions to the disease. Alzheimer's disease<sup>17</sup>, breast cancer<sup>18</sup>, and colorectal cancer<sup>19</sup> are a few good examples using systematic meta-analyses with consensus outcomes.

Establishing robust evidence of genetic predisposition to lung cancer risk has a potential clinical utility for not only population risk stratification but also primary prevention. The main objective of our study was to identify, consolidate, and interpret genetic associations of common variants with lung cancer using a comprehensive research synopsis and systematic meta-analysis. We attempted to systematically evaluate all published candidate-gene association studies in lung cancer following credible guidelines, which were used to guide and standardize these field synopses<sup>20-22</sup>. Additionally, for variants with significant associations by meta-analysis, we applied Venice criteria<sup>21</sup> proposed by the Human Genome Epidemiology Network (HuGENet) to assess the epidemiological credibility of cumulative epidemiological evidence of these associations, so as to obtain more reliable results. Moreover, to get a better insight of the differences in genetic variations among populations with different characters, associations stratified by ethnicity, histological types, and smoking status were also examined.

#### Results

Among the final 1,018 eligible publications for our meta-analysis (Fig. 1), vast majority (n = 926, 91%) were published after 1999, and 684 (67%) of these papers were published over the past decade (2006~2015) (Supplementary Fig. S1). A total of 2,910 genetic variants from 754 unique candidate genes or loci were eligible for further analyses. The included studies had a mean of 414 cases (range 13–4257) and 565 controls (range 12–55823). Among the 2,910 variants, 254 were reported in at least three independent datasets, and eight had been reported as the top association variants with lung cancer (P <  $5 \times 10^{-8}$ ) in published GWAS<sup>8, 9, 23, 24</sup>. Therefore, our meta-analyses were focused on the remaining 246 genetic variants in 138 genes or loci (Supplementary Table S1). More detailed information of the variants was presented in the Supplementary Results.

**Main meta-analyses.** For the 246 variants, we first conducted 246 main meta-analyses, one for each variant. On average, these analyses had 6,315 subjects (range 397–71120) and were combined from eight studies (range 3–133) (Supplementary Table S1). The allelic model was performed for all but nine because of insufficient available data from the original studies (Supplementary Table S1). Of the 246 main meta-analyses, 56 variants within 45 different genes showed nominally significant genetic associations with lung cancer (*p*-value < 0.05) (Table 1, Supplementary Table S2). The strength of association between each genetic variant and lung cancer as measured by ORs had the mean of 1.36 (range 1.08–2.55) for putative "risk" variants and 0.78 (range 0.55–0.90) for putative "protective" variants. Of the 56 main meta-analyses with significant results, 24 had little or no heterogeneity, 16 had evidence of potential bias (publication bias, small study effects, or excess significance bias), and 16 were lack of robustness based on the sensitivity analyses. More details of the results were presented in the Supplementary Results.

The credibility assessment of the cumulative epidemiological evidence found eight genetic variants (*APEX1* rs1760944, *AXIN2* rs2240308, *CHRNA3* rs6495309, *CXCR2* rs1126579, *CYP2E1* rs6413432, *HYKK* rs931794, *PON1* rs662, and *REV3L* rs462779) were strong and ten were moderate (*ATM* rs189037, *CD3EAP* rs967591, *CYP2A6* rs1801272, *HIF1A* rs11549467, *PDCD5* rs1862214, *PROM1* rs2240688, *TP53* rs12951053, *TP63* rs10937405, *WWOX* CNV-67048, and *XRCC1* rs3213255) (Table 1, Supplementary Table S2).

In the dominant genetic model analyses (Supplementary Table S1), 44 variants showed significant associations with lung cancer risk, of which seven had non-significant association in the main allelic meta-analyses yet, interestingly, two (*ATM* rs66467 and *REV3L* rs465646) showed strong and moderate cumulative epidemiological evidence, respectively (Table 2, Supplementary Table S2). Under the recessive model, 39 variants showed statistically significant associations, of which ten were non-significant under an allelic model. However, none of these showed strong cumulative epidemiologic evidence, although five variants (*CASC8* rs6983267, *CHRNA5* rs142774214, *CYP2A6* non\*4/\*4, *IL17A* rs2275913, and *XPA* rs1800975) showed moderate evidence (Table 2).

**Subgroup meta-analyses.** *Ethnicity.* Subgroup meta-analyses were conducted in Caucasian and Asian population separately under each of the three genetic models (allelic, dominant, or recessive model) depending on the available data (Supplementary Table S3). We found that 19 and 26 variants were significantly associated with lung cancer susceptibility in Caucasian and Asian population, respectively. Five variants (*APEX1* rs1130409, *CHRNA5* rs16969968, *CLPTM1L* rs402710, *ERCC2* rs13181, and *SOD2* rs4880) showed strong and five (*CYP1A2* rs762551, *CYP1B1* rs1056836, *CYP2A6* rs1801272, *CYP2E1* rs2031920, and *XRCC1* rs1799782) showed moderate evidence in the Caucasian population (Table 3, Supplementary Table S4). For the significant variants in the Asian population, strong and moderate cumulative evidence were observed in seven (*APEX1* rs1760944, *CLPTM1L* rs402710, *CYP2E1* rs6413432, *MIR146A* rs2910164, *MIR196A2* rs11614913, *REV3L* rs462779, and *TERT* rs2736098) and seven variants (*ATM* rs189037, *CHRNA3* rs6495309, *CYP2A6* non\*4/\*4, *GSTT1* present/null, *PROM1* rs2240688, *REV3L* rs465646, and *WWOX* CNV-67048), respectively (Table 3, Supplementary



Figure 1. Flowchart of literature search and selection for meta-analyses for candidate-gene association studies of lung cancer.

Table S4). Comparing the significant variants across ethnic groups, we found that 13 variants (*AGER* rs1800624, *ATM* rs189037, *CYP2A6* non\*4/\*4, *FASLG* rs763110, *IL10* rs1800872, *MAPKAPK2* CNV-30450, *MIR196A2* rs11614913, *PROM1* rs2240688, *REV3L* rs462779, *REV3L* rs465646, *VEGFA* rs833061, *WWOX* CNV-67048, and *XRCC1* rs25487) were unique to the Asian population, and seven (*APEX1* rs1130409, *CYP1A2* rs762551, *CYP2A6* rs1801272, *ELANE* rs351107, *ELANE* rs7254054, *HRAS1* a VNTR variation, and *MTHFR* rs1801131) to Caucasian population. Four variants (*CLPTM1L* rs402710, *CYP1A1* rs4646903, *CYP1A1* rs1048943, and *GSTM1* present/null) shared between the two groups, including one (*CLPTM1L* rs402710) showed consistent strong evidence of significant associations in both groups (Supplementary Fig. S2).

Histological types of lung cancer. Considering the etiologic differences of different subtypes of lung cancer, subgroup meta-analyses were performed for genetic variants with data available for non-small cell lung cancer [NSCLC], small cell lung cancer [SCLC], adenocarcinoma [AD], and squamous cell carcinoma [SCC] under each of the three genetic models (allelic, dominant, or recessive model) (Supplementary Table S5). In the NSCLC subgroup, statistical significant associations were found for 25 variants where eight variants (CHRNA5 rs16969968, CLPTM1L rs402710, CYP2E1 rs6413432, ERCC1 rs11615, FGFR4 rs351855, HYKK rs931794, MIR146A rs2910164, and TERT rs2736098) demonstrated strong cumulative epidemiological evidence (Table 3, Supplementary Table S6). In the SCLC group, five variants showed significant associations but all were moderate or weak cumulative evidence. Three significant variants (CHRNA5 rs16969968, CYP1A1 rs4646903, and GSTM1 present/null) shared between the NSCLC and SCLC group (Supplementary Fig. S3). For the AD group, 15 variants showed significant associations where four of them have strong evidence (CYP2E1 rs6413432, OGG1 rs1052133, TERT rs2736098, and TP53 rs1042522). As for SCC, two out of eight significant variants (CYP1A1 rs4646903 and CYP2E1 rs6413432) showed strong cumulative evidence. Four significant variants (CYP2E1 rs6413432, GSTM1 present/null, SOD2 rs4880, and TERT rs2736098) were shared between the AD and SCC group, including one (CYP2E1 rs6413432) showed consistent strong evidence of significant associations in both groups (Supplementary Fig. S4).

				Number	evaluated	Genetic ass	Genetic associations with lung cancer Heterogeneity		geneity		Venice	Credibility	
Genes	Variants*	Frequency (%) <sup>†</sup>	Ethnicity	Studies	Cases/ Controls	Contrast <sup>¶</sup>	OR(95%CI)	p value	I <sup>2</sup> (%)	P <sub>Q</sub>	Begg P	criteria grades <sup>∫</sup>	of evidence <sup>§</sup>
APEX1	rs1760944(A/C)	47.94	All	8	3588/3783	A vs C	1.16(1.08-1.25)	$2.85  imes 10^{-5}$	9	0.360	0.386	AAA	Strong
AXIN2	rs2240308(T/C)	37.40	All	3	758/742	T vs C	0.73(0.63-0.85)	$6.39\times10^{-5}$	0	0.398	1.000	AAA	Strong
CHRNA3	rs6495309(T/C)	38.44	All	4	3381/4244	T vs C	0.83(0.77-0.89)	$6.55 imes10^{-8}$	0	0.427	1.000	AAA	Strong
CXCR2	rs1126579(T/C)	55.45	All	3	942/964	T vs C	0.84(0.74-0.96)	0.009	0	0.967	1.000	AAA	Strong
CYP2E1	rs6413432(A/T)	22.17	All	14	2944/3347	A vs T	0.78(0.71-0.85)	$6.76 imes10^{-8}$	0	0.821	0.827	AAA	Strong
НҮКК	rs931794(G/A)	32.89	All	5	2435/3180	G vs A	1.23(1.14-1.34)	$1.85  imes 10^{-7}$	0	0.864	1.000	AAA	Strong
PON1	rs662(A/G)	46.70	All	3	995/834	A vs G	0.77(0.67-0.88)	$2.02  imes 10^{-4}$	0	0.701	1.000	AAA	Strong
REV3L	rs462779(T/C)	39.36	Asian <sup>‡</sup>	4	1937/2335	T vs C	1.11(1.02-1.22)	0.021	0	0.911	0.734	AAC	Strong
ATM	rs189037(A/G)	42.68	Asian <sup>‡</sup>	5	3036/3415	A vs G	1.09(1.00-1.18)	0.050	29	0.227	0.806	ABC	Moderate
CD3EAP	rs967591(A/G)	32.09	All	3	676/726	A vs G	1.23(1.01-1.49)	0.036	22	0.278	1.000	BAA	Moderate
CYP2A6	rs1801272(A/T)	3.99	Caucasian <sup>‡</sup>	3	2411/2644	carriers vs non- carriers	0.66(0.52-0.84)	0.001	0	0.674	1.000	BAB	Moderate
HIF1A	rs11549467(A/G)	9.45	All	3	509/566	A vs G	2.27(1.74-2.96)	$1.62  imes 10^{-9}$	0	0.481	0.296	BAA	Moderate
PDCD5	rs1862214(G/C)	32.06	All	3	737/683	G vs C	1.32(1.12-1.56)	0.001	0	0.395	0.296	BAB	Moderate
PROM1	rs2240688(C/A)	27.37	Asian <sup>‡</sup>	3	2332/2457	C vs A	0.83(0.76-0.91)	$6.92  imes 10^{-5}$	0	0.991	0.296	AAB	Moderate
TP53	rs12951053(G/T)	9.93	All	3	475/569	G vs T	1.57(1.11-2.23)	0.011	37	0.203	0.296	BBB	Moderate
TP63	rs10937405(T/C)	42.62	All	4	4927/8794	T vs C	0.87(0.81-0.94)	$2.20 imes10^{-4}$	34	0.207	0.308	ABA	Moderate
wwox	CNV-67048	2.86	Asian <sup>‡</sup>	4	2942/3074	0 copy vs 2 copies	2.06(1.58-2.70)	$1.20  imes 10^{-7}$	0	0.911	1.000	BAB	Moderate
XRCC1	rs3213255(G/A)	38.15	All	3	1089/1506	G vs A	1.21(1.08-1.35)	0.001	0	0.457	0.296	AAB	Moderate
AGER	rs1800624(A/T)	34.41	Asian <sup>‡</sup>	3	1656/1693	A vs T	1 18(1 04–1 33)	0.010	16	0.305	1 000	AAC	Weak
BCL2	rs2279115(A/C)	43.37	All	5	1847/2367	A vs C	0.65(0.46-0.91)	0.011	91	0.000	0.624	ACC	Weak
CHRNA 3	rs578776(T/C)	31.98	All	3	1245/2009	TvsC	0.87(0.77-0.98)	0.011	0	0.000	1 000	AAC	Weak
CHRNA3	rs938682(C/T)	28.37	All	3	1240/1986	CvsT	0.86(0.76-0.96)	0.009	0	0.582	0.296	AAC	Weak
CHDNA3	rs12914385(T/C)	35.09	A 11	4	5356/2873	TreC	$1.20(1.01 \cdot 1.44)$	0.009	76	0.007	0.230		Weak
CHRNAS	ro16060068(A/C)	22 51		11	6222/62452	1 vs C	1.20(1.01-1.44)	0.044	20	0.007	0.734	ACA	Week
CIPTMII	rs402710(T/C)	32.51		13	7214/8051	TreC	0.89(0.83, 0.95)	$2.63 \times 10^{-4}$	38	0.000	0.119	ABC	Weak
CVP1A1	rs4646903(C/T)	21.88	A11	57	9844/12410	C ve T	1.16(1.07-1.25)	$1.59 \times 10^{-4}$	55	0.070	0.009	ACC	Weak
CVP1A1	rs1048943(G/A)	17.83	A11	54	9869/12114	G vs A	1.10(1.0) - 1.23(1)	$7.64 \times 10^{-5}$	67	0.000	0.772	ACC	Weak
CVP1R1	rs1056836(G/C)	38.50	A11	12	3033/3866	GveC	1.23(1.11-1.30) 1.13(1.05-1.22)	0.002	0	0.551	0.049	AAC	Weak
CVP246	rs5031016(C/T)	0.80		3	1527/1138	C ve T	0.57(0.33, 1.00)	0.002	73	0.025	0.004	BCC	Weak
CVD2E1	rs2031020(T/C)	17.33		23	1083/6628	TreC	0.37(0.33-1.00)	0.040	50	0.023	0.290	ACA	Weak
ELANE	rs351107(G/T) (-903T > G, Rep a)	5.31	Caucasian <sup>‡</sup>	3	745/762	G vs T	0.55(0.34-0.87)	0.013	29	0.246	1.000	BBC	Weak
ELANE	rs7254054(A/G) (-741G>A, Pap b)	27.20	Caucasian <sup>‡</sup>	3	754/750	A vs G	0.77(0.61-0.97)	0.030	46	0.155	0.296	BBC	Weak
EDCC1	rep_0)	E1 10	A 11	12	5721/7059	C m T	0.00(0.83, 0.00)	0.023	52	0.019	0.086	ACC	Weelr
ERCC2	ro228406(A/C)	40.05		6	1754/2699	A ve C	1.12(1.02 - 1.23)	0.025	0	0.018	0.000	ACC	Week
ERCC2	rs13181(C/A)	25.26	A 11	40	13111/167/0	C ve A	1.12(1.02-1.23)	$4.18 \times 10^{-4}$	10	0.000	0.200	ABC	Weak
ERCC5	rs1047768(T/C)	43.99	A11	40	1449/2248	TysC	0.86(0.74 - 1.00)	0.049	48	0.123	0.734	ABC	Weak
ERCC6	rs3793784(G/C)	30.82	A11	3	1643/1689	G vs C	0.30(0.74 - 1.00)	0.049	68	0.125	1 000	ACA	Weak
EGER4	rs351855(A/G)	42.47	A11	4	1043/1275	A vs G	0.73(0.69-0.92)	0.007	33	0.214	0.089	ABC	Weak
GSTM1	Present/null	48.85	All	133	33253/37867	null vs	1.18(1.12-1.23)	$2.54 \times 10^{-11}$	52	0.000	0.105	ACC	Weak
CCTD1		20.41	A 11	16	10501/14411	present	1.00(1.02, 1.15)	0.011		0.000	0.075	100	<b>147.</b> . 1.
GSTF1	GSTT1	26.14	All	40 77	23009/25365	null vs	1.08(1.02-1.13) 1.10(1.02-1.19)	0.011	58	0.000	0.346	ACC	Weak
		20111			20003/20000	present	1110(1102 1113)	0.011		0.000	0.010		
HRAS1	VNTR(common alleles/rare alleles)	7.03	Caucasian <sup>‡</sup>	4	746/1174	rare vs common	2.55(1.01-6.45)	0.048	69	0.023	0.734	BCC	Weak
IL10	rs1800896(G/A)	37.18	All	10	2861/3817	G vs A	1.29(1.05-1.59)	0.017	75	0.000	0.074	ACC	Weak
MAPKAPK2	CNV-30450	9.76	Asian <sup>‡</sup>	3	2332/2480	4 copies vs 2 copies	1.60(1.04-2.45)	0.031	81	0.005	1.000	ВСВ	Weak
MDM2	rs2279744(G/T)	41.05	All	19	11076/14434	G vs T	1.10(1.01-1.19)	0.021	75	0.000	0.700	ACC	Weak
MIR146A	rs2910164(C/G)	45.26	All	6	3158/3225	C vs G	1.16(1.06-1.27)	0.001	21	0.274	0.260	AAC	Weak
MMP2	rs243865(T/C)	16.77	All	3	1751/1729	T vs C	0.63(0.45-0.89)	0.009	80	0.007	0.296	BCC	Weak
Continued													

				Number evaluated		Genetic ass	ociations with lu	ng cancer	Heterogeneity			Venice	Credibility
Genes	Variants*	Frequency (%) <sup>†</sup>	Ethnicity	Studies	Cases/ Controls	Contrast <sup>¶</sup>	OR(95%CI)	p value	I <sup>2</sup> (%)	P <sub>Q</sub> I	Begg P	criteria grades∫	of evidence <sup>§</sup>
MTRR	rs1801394(G/A)	43.28	All	3	1668/2291	G vs A	1.13(1.03-1.24)	0.011	0	0.525	1.000	AAC	Weak
NOD2	rs2066847 (3020insC/-)	0.50	All	3	807/4078	carriers vs non- carriers	1.42(1.07-1.90)	0.017	0	0.593	1.000	×AC	Weak
SFTPB	wild type/ variation	5.83	All	3	157/240	variation vs wild	1.92(1.11-3.33)	0.020	0	0.960	0.296	CAB	Weak
SOD2	rs4880(T/C)	51.48	All	9	3738/4467	T vs C	1.20(1.06-1.36)	0.005	61	0.009	0.348	ACA	Weak
TERT	rs2736098(A/G)	33.01	All	7	4660/4825	A vs G	1.20(1.08-1.33)	0.001	67	0.006	0.548	ACB	Weak
UGT1A6	rs6759892(G/T)	25.10	All	3	266/261	G vs T	2.27(1.14-4.53)	0.020	84	0.002	1.000	BCA	Weak
XRCC1	rs1001581(T/C)	34.52	All	5	851/1166	T vs C	1.17(1.00-1.37)	0.044	28	0.232	0.221	ABC	Weak
XRCC1	rs1799782(T/C)	18.19	All	30	11096/13772	T vs C	0.90(0.82-0.98)	0.022	62	0.000	0.372	ACC	Weak
XRCC1	rs3213245(C/T)	11.03	All	5	2795/2865	C vs T	1.29(1.04-1.59)	0.020	68	0.014	0.806	ACC	Weak

**Table 1.** Genetic variants with significant associations with lung cancer risk in main meta-analyses (Continued on next page) OR = odds ratio; 95% CI = 95% confidence interval. VNTR = variable number of tandem repeats. CNV = copy number variation. ins = insertion. \*Minor alleles/major alleles (per Caucasian); majors alleles were treated as reference alleles in the analyses. <sup>†</sup>Frequency of minor allele or effect genotype (s) in controls in main meta-analyses. <sup>¶</sup>Allelic contrast or phenotype trait for common variants; genetic comparison for rare variants or variants only with genotype group data. <sup>¶</sup>P value of the test for between-study heterogeneity. <sup>¶</sup>Venice criteria grades are for amount of evidence, replication of the association, and protection from bias; one rare variant was not scored for amount of evidence (×). <sup>§</sup>Credibility of evidence is categorized as "strong", "moderate", or "weak" for association with lung cancer risk. <sup>‡</sup>Only Asian or Caucasian data were available for meta-analysis.

.....

*Smoking status.* As for subgroup meta-analyses by smoking status, significant associations were found for twenty-two variants and ten variants in the smokers and the non-smokers, respectively. In the smoker population, the significant associations only showed moderate (*APEX1* rs1760944, *CYP1A1* rs4646903, *CYP2A6* non\*4/\*4, *CYP2E1* rs6413432, *CYP2E1* rs2031920, *GSTP1* rs1138272, and *NBN* rs1805794) or weak cumulative evidence, mostly due to lack of large-scale evidence and the presence of potential biases (Table 3, Supplementary Table S8). In the non-smokers populations, the significant associations had strong, moderate, or weak evidence for one (*ERCC1* rs11615), six (*CYP2E1* rs6413432, *CYP2E1* rs2031920, *ERCC2* rs13181, *GSTM1* present/null, *TP53* rs1042522, and *XRCC1* rs3213245), and three variants, respectively. Comparing the significant variants between two groups, seventeen were unique to the smoking population, five to the non-smoking population, and five shared between the two populations (Supplementary Fig. S5).

**Functional annotations.** Based on main and subgroup meta-analyses, a total of 22 variants showed significant associations to lung cancer susceptibility with strong cumulative evidence. We further performed genomic annotations for these variants using HaploReg v4.1<sup>25</sup>, which can help to predict the functional variants. Of them, twelve variants are located in exon, two in microRNA (miRNA), and the others in non-coding regions (four intronic, two intergenic, one 5'UTR, and one 3'UTR) (Table 4). Most of these variants are located within enhancer or promoter elements that are active across a wide range of tissue types (including lung cancer or normal lung tissues). Furthermore, majority of these 22 variants have been identified as expression quantitative trait loci (eQTLs) of a number of genes in various tissue types including normal lung tissues. The functional potential of ten non-synonymous SNPs were further predicted using PolyPhen-2<sup>26</sup>. The variant rs351855 may result in a probably damaging effect on FGFR4 function. The other non-synonymous SNPs were predicted to be "benign".

**Non-significant associations.** Non-significant associations for 150 variants within 98 genes were found under any genetic model (allelic, dominant, or recessive model) in both main and subgroup meta-analyses (Supplementary Table S9). Among these 150 variants, credibility of cumulative epidemiological evidence were identified as strong, moderate, or weak for seven (*ERCC1* rs16979802, *ERCC1* rs2298881, *ERCC1* rs735482, *POLI* rs3730668, *PPARG* rs1801282, *PTGS2* rs20417, and *TNF* rs1799724), four (*ERCC2* rs1799793, *TYMS* 28-bp tandem repeat, *XPC* rs2228000, and *XRCC3* rs861539), and 139 variants, respectively (Supplementary Table S9).

#### Discussion

To the best of our knowledge, this systematic meta-analysis is the largest and most comprehensive assessment of currently available literatures on candidate-gene association studies in lung cancer. This study examined associations between genetic variants and lung cancer risk using data from 1,018 candidate-gene association studies including 2,910 genetic variants. The meta-analyses and evidence evaluations allowed us to identify 22 genetic variants in 21 genes with strong evidence of associations with lung cancer risk. For these variants, additional genomic annotation information provided evidence of putative regulatory functions, including regulatory histone modification marks, DNase I hypersensitivity, motif changed, and transcription factor binding in multiple cell types including lung tissue.

Variants in non-coding region associated with lung cancer risk may have their effects through transcription, mRNA stability, protein structure/function, or binding sites of miRNA<sup>27</sup>. For example, the variant rs1760944 (-656T > G) at the 5'-promoter region of *APEX1*<sup>28</sup> was shown as a significant variant (T vs. C allele, OR 1.16,

				Number evaluated		Genetic asso	ociations with lung	Heterogeneity			Venice		
Genes	Variants	Alleles*	MAF (%)	Studies	Studies Cases/ Controls		Genetic models OR(95%CI)		$ \mathbf{I}^2(\%)  \mathbf{P}_{\mathbf{Q}}  $		Begg P	criteria grades <sup>†</sup>	Credibility of evidence <sup>‡</sup>
ATM	rs664677	C/T	58.90	3	1627/1641	Dominant	0.76(0.64-0.92)	0.004	0	0.448	1.000	AAA	Strong
REV3L	rs465646	C/T	18.18	3	1296/1511	Dominant	0.78(0.67-0.92)	0.003	0	0.437	1.000	BAB	Moderate
CASC8	rs6983267	G/T	44.77	3	1539/1989	Recessive	1.22(1.04-1.44)	0.013	0	0.644	0.296	BAA	Moderate
CHRNA5	rs142774214	ins/-	37.67	3	1431/1606	Recessive	0.80(0.65-0.98)	0.032	0	0.597	1.000	BAA	Moderate
CYP2A6	non*4/*4	del/-	13.48	7	2623/2380	Recessive	0.51(0.35-0.73)	$2.93 imes10^{-4}$	0	0.539	1.000	BAA	Moderate
IL17A	rs2275913	A/G	24.90	3	889/998	Recessive	1.76(1.21-2.55)	0.003	18	0.295	0.296	BAB	Moderate
XPA	rs1800975	A/G	36.74	12	4221/5240	Recessive	1.22(1.05-1.42)	0.011	33	0.124	0.681	ABA	Moderate
Chr8q24	rs16901979	A/C	19.48	3	1534/1992	Dominant	1.18(1.02-1.37)	0.025	0	0.610	1.000	AAC	Weak
CYP1B1	rs10012	G/C	25.98	3	622/666	Dominant	1.69(1.05-2.72)	0.031	74	0.021	1.000	BCC	Weak
EGF	rs4444903	G/A	59.28	3	666/690	Dominant	2.07(1.01-4.24)	0.048	79	0.009	0.296	ACC	Weak
MLH1	rs1800734	A/G	48.86	5	2178/2320	Dominant	0.80(0.68-0.95)	0.009	24	0.260	0.462	AAC	Weak
PTGS2	rs689466	G/A	38.07	4	1676/2180	Dominant	0.78(0.62-0.97)	0.026	56	0.076	0.734	ACA	Weak
FASLG	rs763110	T/C	34.01	5	4436/4120	Recessive	0.83(0.70-0.99)	0.038	30	0.221	0.462	ABC	Weak
IL1B	rs1143627	C/T	38.81	8	4201/5431	Recessive	0.80(0.68-0.95)	0.010	49	0.059	0.019	ABC	Weak
LIG1	rs156641	A/G	31.71	3	1112/2048	Recessive	1.45(1.14-1.83)	0.002	0	0.370	1.000	BAC	Weak
XRCC1	rs25487	A/G	29.70	48	16999/20567	Recessive	1.16(1.03-1.30)	0.018	54	0.000	0.729	ACC	Weak
XRCC3	rs1799794	G/A	41.09	4	1389/1941	Recessive	0.82(0.67-0.99)	0.038	0	0.469	1.000	BAC	Weak

**Table 2.** Genetic variants with significant associations with lung cancer risk under a dominant or recessive genetic model. MAF = minor allele frequency in controls. OR = odds ratio; 95% CI = 95% confidence interval. chr = chromosome. ins = insertion. del = deletion. bp = base pair. \*Minor alleles/major alleles (per Caucasian); major alleles were treated as reference alleles in the analyses; Dominant model, summary OR was estimated for subjects who carry one or two minor alleles. Recessive model, summary OR was estimated for subjects have homozygous of the minor alleles. 'P value of the test for between-study heterogeneity. <sup>†</sup>Venice criteria grades are for amount of evidence, replication of the association, and protection from bias; one rare variant was not scored for amount of evidence (×). <sup>‡</sup>Credibility of evidence is categorized as "strong", "moderate", or "weak" for association with lung cancer risk.

95%CI 1.08-1.25) with strong cumulative evidence. This variant is predicted to influence promoter histone marks in 24 tissues including lung and lung cancer cell lines. Previous in vitro promoter assay has detected that the rs1760944 T allele significantly lowered promoter activity than that of the G allele, which indicated the variant allele (T) may be associated with a low transcriptional activity of the APEX1 in lung cancer cells<sup>28</sup>. The variant rs6495309 in CHRNA3/B4 intergenic region<sup>12</sup> showed strong evidence of association with lung cancer susceptibility in our meta-analysis. This finding was consistent with the results from a previous meta-analysis performed in Chinese population<sup>29</sup>, and a recent meta-analysis performed on the basis of GWASs of lung cancer<sup>15</sup>. Additional subgroup analysis of Asians in our study also showed the risk effect for the rs6495309 C allele. This SNP overlaps with promoter histone marks and alters regulatory motif. Functional study also demonstrated that the rs6495309 C allele significantly increased the CHRNA3 expression through altering the ability of CHRNA3 promoter binding to the transcriptional factor Oct- $1^{12}$ . A common genetic variation rs1126579 (C > T) located in the 3'UTR of the CXCR2 (IL8RB) was found to be associated with a reduced risk of lung cancer with strong evidence. The HaploReg tool identified that rs1126579 was an eQTL for a number of genes including CXCR2. Previous studies also reported that CXCR2 was down regulated in lung cancer tissue and might play a suppressive role in lung cancer via the p53-dependent senescence<sup>30, 31</sup>. Functional data indicated that the rs1126579 variant can disrupt the binding site of miR-516a-3p and further increase the expression of CXCR2<sup>30</sup>, which may also explain why rs1126579 showed a protective effect on the risk of lung cancer.

Variants falling within coding regions, especially non-synonymous SNPs, could have some effects on protein structure, function, or expression level, which may explain its association with the susceptibility of disease<sup>32</sup>. For example, the non-synonymous *CHRNA5* rs16969968 (Asp398Asn) causes an amino acid substitution at codon 398 of the CHRNA5 protein. And the aspartic acid (Asp398) is located at the central part of the second intracellular loop in the structure of CHRNA5 protein, and was reported highly conserved across multiple species<sup>10</sup>. The rs1042522 (Arg72Pro) is a common functional SNP in the exon 4 of *TP53*, which encodes an important tumor suppressor protein. *TP53* gene is often mutated in NSCLC tumors, an early event in development of lung cancer<sup>33</sup>. Further functional data showed that the 72Pro allele carriers of lung cancer patients may have a low frequency of the *TP53* mutations in tumors<sup>34</sup>. The rs351855 (Gly388Arg) influences the transmembrane domain of the FGFR4 protein<sup>35</sup>. This SNP resides in a conserved region and causes a possibly damaging effect on protein function of FGFR4 predicted by PolyPhen. Also, rs4800 (Ala16Val) is a non-synonymous SNP in *SOD2*. This SNP with valine variation can reduce enzyme activity<sup>36</sup> and further increase oxidative stress. Rs2736098 is a synonymous SNP (Asn305Asn) in exon 2 of the *TERT* gene, which is a well known oncogene and encodes the catalytic subunit of the telomerase<sup>37</sup>. This SNP may have association with telomere length<sup>38</sup>. Although it does not change protein amino acid, this SNP is located within the gene regulatory elements and may alter transcription factor binding.

AmeNomeNomeNomeNomeNo <th< th=""><th></th><th></th><th></th><th colspan="2">Number evaluated</th><th>Lung-cancer</th><th>risk meta-analysis</th><th colspan="2">Heterogeneity</th><th></th><th>Venice</th><th></th></th<>				Number evaluated		Lung-cancer	risk meta-analysis	Heterogeneity			Venice		
Gene         Mandey         Name         Number         Number <th></th> <th></th> <th></th> <th>a. 1</th> <th>Cases/</th> <th>Genetic</th> <th>0.0.000</th> <th></th> <th>I<sup>2</sup></th> <th></th> <th></th> <th>criteria</th> <th>Credibility</th>				a. 1	Cases/	Genetic	0.0.000		I <sup>2</sup>			criteria	Credibility
Altal         Gamma         Gamma <t< th=""><th>Gene</th><th>Subgroup</th><th>Variants*</th><th>Studies</th><th>Controls</th><th>models</th><th>OR(95%CI)</th><th>p value</th><th>(%)</th><th>P<sub>Q</sub>∥</th><th>Begg P</th><th>grades</th><th>of evidence<sup>9</sup></th></t<>	Gene	Subgroup	Variants*	Studies	Controls	models	OR(95%CI)	p value	(%)	P <sub>Q</sub> ∥	Begg P	grades	of evidence <sup>9</sup>
CHACMA CHACMACanada CanadaCanada Canada Canada Canada CanadaCanada Cana	APEXI	Caucasian	rs1130409(G/T)	7	1807/3065	Recessive	0.84(0.72-0.97)	0.021	0	0.695	0.764	AAA	Strong
LarnadeLarnadeLarnadeMatheMatheMonor </td <td>CHRNA5</td> <td>Caucasian</td> <td>rs16969968(A/G)</td> <td>6</td> <td>3305/59/80</td> <td>Allelic</td> <td>1.35(1.27–1.44)</td> <td><math>2.03 \times 10^{-21}</math></td> <td>0</td> <td>0.958</td> <td>0.990</td> <td>AAA</td> <td>Strong</td>	CHRNA5	Caucasian	rs16969968(A/G)	6	3305/59/80	Allelic	1.35(1.27–1.44)	$2.03 \times 10^{-21}$	0	0.958	0.990	AAA	Strong
Laked Cancenary networksLakes Lakes LakesLakes Lakes LakesLakes Lakes LakesLakes Lakes LakesLake	CLPIMIL	Caucasian	rs402710(17C)	4	1801/1908	Allelic	0.86(0.78-0.94)	0.002	0	0.532	0.734	AAA	Strong
ADMCCancerCancerDisplayDi	ERCC2	Caucasian	rs13181(C/A)	18	5967/8851	Recessive	1.15(1.04–1.29)	0.009	16	0.258	0.495	AAA	Strong
CH7PMCanactamindexisionMontameReseareLondLondModeModeModeCPTPMCanactaminfibilizationSectorSect	SOD2	Caucasian	rs4880(1/C)	4	3185/3966	Allelic	1.17(1.10-1.25)	2.24 × 10 <sup>-6</sup>	0	0.973	0.406	AAA	Strong
ChrizeCanactaminitional solutionJoin MathJoin Mat	CYPIA2	Caucasian	rs/62551(C/A)	3	869/1468	Recessive	1.69(1.20-2.36)	0.002	30	0.232	1.000	BBA	Moderate
Chr2heCanadamInitial TaylerJJ <td>CYP1B1</td> <td>Caucasian</td> <td>rs1056836(G/C)</td> <td>6</td> <td>1849/2655</td> <td>Dominant</td> <td>1.18(1.04–1.34)</td> <td>0.010</td> <td>0</td> <td>0.856</td> <td>0.711</td> <td>AAB</td> <td>Moderate</td>	CYP1B1	Caucasian	rs1056836(G/C)	6	1849/2655	Dominant	1.18(1.04–1.34)	0.010	0	0.856	0.711	AAB	Moderate
CH220CH230CH2300Abiel <t< td=""><td>CYP2A6</td><td>Caucasian</td><td>rs1801272(A/T)</td><td>3</td><td>2411/2644</td><td>Dominant</td><td>0.66(0.52-0.84)</td><td>0.001</td><td>0</td><td>0.674</td><td>1.000</td><td>BAB</td><td>Moderate</td></t<>	CYP2A6	Caucasian	rs1801272(A/T)	3	2411/2644	Dominant	0.66(0.52-0.84)	0.001	0	0.674	1.000	BAB	Moderate
ARCHCalcalantn1/9978/LTC124740/688Allicit084007-20890.300.80.100.40AllowModernelCPTPMAisann1402710C/C851710861.010.64007-2091.53 × 10°170.4087.00AllowStructureCPTPMAisann6402710C/C851410640.8007-0801.53 × 10°100.0 <td>CYP2E1</td> <td>Caucasian</td> <td>rs2031920(T/C)</td> <td>6</td> <td>665/1224</td> <td>Allelic</td> <td>0.61(0.42-0.90)</td> <td>0.013</td> <td>0</td> <td>0.456</td> <td>0.837</td> <td>BAB</td> <td>Moderate</td>	CYP2E1	Caucasian	rs2031920(T/C)	6	665/1224	Allelic	0.61(0.42-0.90)	0.013	0	0.456	0.837	BAB	Moderate
Areal         Areal         Ball (AR)         S all (AR)         Areal         Ball (AR)         0	XRCCI	Caucasian	rs1799782(1/C)	12	4/40/6868	Allelic	0.84(0.72-0.98)	0.028	28	0.172	0.790	ABA	Moderate
Chronian         Name         Fill         Name         Strate         Dial         Dia         Dial         Dial	APEXI	Asian	rs1760944(A/C)	5	30/1/3038	Allelic	1.20(1.12–1.29)	9.14 × 10 <sup>-7</sup>	0	0.717	0.462	AAA	Strong
CH2P2         Name         Indel 44 (AU/L)         0         Use of Mark         All         Number of Mark	CLPIMIL	Asian	rs402710(17C)	8	5413/6143	Dominant	0.84(0.77-0.92)	1.53 × 10 <sup>-4</sup>	17	0.296	0.711	AAA	Strong
Minkmmichal (modical)iMark	CYP2E1	Asian	rs6413432(A/T)	6	1964/2085	Allelic	0.78(0.70-0.86)	1.31×10 <sup>-6</sup>	0	0.824	0.707	AAA	Strong
MINDPOR         Asian         Inferial PULCI         4         Zind         Dimma         Lind         Lind         0        0     <	MIR146A	Asian	rs2910164(C/G)	4	2807/2841	Recessive	1.23(1.09–1.39)	0.001	0	0.594	1.000	AAA	Strong
Riker         Akanom         rakerSyn(L)C         4         197.03         Allein         111(L02-L23         0.01         0.	MIR196A2	Asian	rs11614913(C/T)	4	2376/2413	Dominant	1.22(1.07-1.38)	0.002	0	0.444	0.308	AAA	Strong
IAM         Asian         FX/4008/AU         5         369/392         Domum         L00.(14-1.9)         L01.57         10         0.888         L00         AAA         Storp           CHEMA         Ataan         ref93309/TC0         6         305/1727         Allei         0160(10-113)         001         4         0.05         8.0         AMA         Moderate           CHEMA         Asian         ref93309/TC0         6         2517272         Allei         03307-690         0.01         4         0.01         8.04         Moderate           ROMI         Asian         ref24088/CU7         3         128111         Alleic         03307-697         0.01         4         0.01         1008         RAB         Moderate           REVIA         Asian         ref24088/CU7         12         12811         Alleic         16307-197         0.01         14         0.00         RAB         Moderate           CYTAI         Safan         ref44903(CT0         12         27275         Alleic         1630(12-14)         1481         13<0.00	REV3L	Asian	rs462779(17C)	4	1937/2335	Allelic	1.11(1.02–1.22)	0.021	0	0.911	0.734	AAC	Strong
AIMAISMISINGRYAICSSMIRINNMIRINNMIRINNMIRINNMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINMIRINN <th< td=""><td>TERT</td><td>Asian</td><td>rs2736098(A/G)</td><td>5</td><td>3829/3992</td><td>Dominant</td><td>1.26(1.14–1.39)</td><td><math>1.03 \times 10^{-5}</math></td><td>0</td><td>0.896</td><td>1.000</td><td>AAA</td><td>Strong</td></th<>	TERT	Asian	rs2736098(A/G)	5	3829/3992	Dominant	1.26(1.14–1.39)	$1.03 \times 10^{-5}$	0	0.896	1.000	AAA	Strong
CHR0AN         Asian         Rede9300(1C)         3         2837277         Alleit         03007-001         10.17         10.10         10.00	ATM	Asian	rs189037(A/G)	5	3036/3415	Allelic	1.09(1.00-1.18)	0.050	29	0.227	0.806	ABC	Moderate
Chr2AcAsianNumbers1015/17240Recave0.2010-0710000.1013100.100340.100340340 <td>CHRNA3</td> <td>Asian</td> <td>rs6495309(1/C)</td> <td>3</td> <td>2635/2767</td> <td>Allelic</td> <td>0.83(0.76-0.91)</td> <td>6.17 × 10<sup>-5</sup></td> <td>27</td> <td>0.254</td> <td>1.000</td> <td>ABA</td> <td>Moderate</td>	CHRNA3	Asian	rs6495309(1/C)	3	2635/2767	Allelic	0.83(0.76-0.91)	6.17 × 10 <sup>-5</sup>	27	0.254	1.000	ABA	Moderate
GATTAsiannullpresent147043/280Allelo1.15(1.07-1000.010340.1056.276.006.276.006.276.006.276.006.276.006.276.00 </td <td>CYP2A6</td> <td>Asian</td> <td>*4/non*4</td> <td>6</td> <td>2517/2264</td> <td>Recessive</td> <td>0.52(0.36-0.75)</td> <td>0.001</td> <td>0</td> <td>0.454</td> <td>0.707</td> <td>BAA</td> <td>Moderate</td>	CYP2A6	Asian	*4/non*4	6	2517/2264	Recessive	0.52(0.36-0.75)	0.001	0	0.454	0.707	BAA	Moderate
PMOM         Asian         r5240688(CN         3         2332137         Alleic         0.030(7-0.9)         0.10         0.10         0.10         0.01         Alleic         0.046rate           RV51A         Asian         CSC40654(CT         3         2332137         Cappy S2         20c1/S-2.70         1.02         0.10         0.11         0.00         RAB         Moderate           CY1A         SCLC         r646903(CT)         1.2         237255         Recesive         1.71(1.08-2.71)         0.021         0.0         0.01         0.0         RAB         Moderate           CY1A         SCLC         rade99988(A')         6         21247257         Alleit         1.01(1.01-1.50         0.01         0.01         0.00         AAB         Moderate           CH7DAT         SCLC         rade1132(CT)         6         2.940400         Alleit         3.610(2.10-1)         1.01         0.0         0.00         AAB         Moderate           CH7DAT         SCLC         rade1132(CT)         7.61133330         0.8101-0         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01	GSTT1	Asian	null/present	14	7043/5289	Allelic	1.15(1.03–1.28)	0.010	34	0.105	0.827	ABA	Moderate
ReV3.         Naian         rede5ele(CP)         3         1296/11         Alleic         0.80,071-097         120         14         0.10         Note         Moderate           WWX         Asian         CNV-57048         4         2942/307         Coppers         206(15.8-270)         1.20 × 10 <sup>-7</sup> 0         0         0.91         0.00         Alleit         Moderate           CTP1AI         SCLC         re464903(CT)         120         122/7255         Alleit         1.30(1.9-2.50         0.004         43         0.00         Alleit         Moderate           CHPAM         SCLC         re1696998(AC)         6         294/0400         Alleit         0.80(7-0.50)         1.00         0.00         AL         0         0.66         1.00         AAA         Strong           CLPTMI         NSCLC         re164332(AT)         6         1290/140         Alleit         0.80(0.7-0.50)         1.00         0.00         AL         0         0.00         AL         0         0.00         AL         0         0.00         AL         0.00         0         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0.00         0	PROM1	Asian	rs2240688(C/A)	3	2332/2457	Allelic	0.83(0.76-0.91)	6.92 × 10 <sup>-5</sup>	0	0.991	0.296	AAB	Moderate
WMCNAAsianCNV-670484942/0700,0007782060178-7010.110.110.0RAMModeral ModeralCTP1ASCLCre464903(C)12732.55Recsive1.71(10-8-2.7)0.010.10.010.000.400.400.400.40GSTMSICCnullpresent121247.75Allen1.31(10-1.5)0.111.30.301.00AAAStoreCIPTMNCCre40210CC62940.40Allen0.507.0011.131.00.00.00AAAStoreCIPTMNSCLCre50150CC1.010.610.510.011.010.01	REV3L	Asian	rs465646(C/T)	3	1296/1511	Allelic	0.83(0.71-0.97)	0.016	14	0.311	1.000	BAB	Moderate
CYP1ASCLCindefasion12273/254Recessive17.1(1.0.8-7.17)0.0100.010.2410.2440.8AModareGSTMSCLCnullpresent2124/275Alkic13.1(1.0.8-7.10)0.00130.301.001.001.00NC <t< td=""><td>WWOX</td><td>Asian</td><td>CNV-67048</td><td>4</td><td>2942/3074</td><td>0 copy vs 2 copies</td><td>2.06(1.58-2.70)</td><td><math>1.20  imes 10^{-7}</math></td><td>0</td><td>0.911</td><td>1.000</td><td>BAB</td><td>Moderate</td></t<>	WWOX	Asian	CNV-67048	4	2942/3074	0 copy vs 2 copies	2.06(1.58-2.70)	$1.20  imes 10^{-7}$	0	0.911	1.000	BAB	Moderate
GXDCnullpressor26124/725Alleix130(109-1.5000.004430.010ModeralModeralCHRNA5NSCCrs1090980K(0)632014736Alleix1.50(12-1.48)1.48 1.01-11130.3290.707ALStrongCLPTMLNSCLCrs40270(TC)620014000Alleix0.80(7)-0911.13 x10-1100.661.00AAStrongCY2E1NSCLCrs611332(AT)337001.08 (0.80, 0.90)1.01 x10-1100.00.00AAStrongFGR4NSCLCrs31155(AG)339.081.08 (0.80, 0.80)1.01 x10-10.01.080.00AAStrongFGR4NSCLCrs31156(AG)49.081.08(1.01, 0.11, 0.11)0.01 10.100.00.000.00AAStrongMIR46ANSCLCrs210916(C)44Molted1.28(1.1-1.40)4.38 x10-10.00.000.01AAStrongTERTNSCLCrs270191(AG)42002/490Alleic1.28(1.1-1.40)4.38 x10-10.00.00.00.00.0ABModeratTERTNSCLCrs270191(AG)333Molte1.28(1.1-1.40)4.38 x10-10.00.00.00.00.00.00.00.00.00.00.00.00.0NAStrongTERTNSCLCrs270191(AG)33Molte1.28(1.1-1.40)<	CYP1A1	SCLC	rs4646903(C/T)	12	273/2545	Recessive	1.71(1.08-2.71)	0.021	0	0.904	0.244	BAA	Moderate
CHRNANNSCLCrelobogenequely69201/4730Alleir1,3(1,24-1.48)1.48 × 10 <sup>-1</sup> 1.31.301.301.00<	GSTM1	SCLC	null/present	26	1224/7255	Allelic	1.30(1.09–1.56)	0.004	43	0.010	1.000	ABA	Moderate
CHPTMINSCLCre40210(T/C)62940/400Alleic0.880,70-0011.1 × 10 <sup>-5</sup> 00.6661.00AAAStrongCYD2E1NSCLCrs614332(AT)6120/1800Alleic0.80(071-0914)90×14 <sup>-0</sup> 1300.8681.00AAAStrongFGCANSCLCrs5155(AG)3780/811Alleic0.80(S8-0.80)101×10 <sup>-5</sup> 100.5000.500AAAStrongFGFANSCLCrs51594(A)41548/244Alleic125(13-13.7)9.8×10 <sup>-6</sup> 00.8800.734AAAStrongMIR46NSCLCrs73098(AG)41548/244Alleic125(13-14.3)9.8×10 <sup>-6</sup> 00.8800.734AAAStrongMIR46NSCLCrs73098(AG)42002/249Alleic126(11-14.6)6.45×10 <sup>-6</sup> 00.8800.734AAAStrongLI7ANSCLCrs109300(C)33587/484Alleic0.72(12-2.65)0.130.810.230.266BAModerateL7ANSCLCrs109307(C)33587/484Alleic0.870.82-0.299.9×10 <sup>-7</sup> 00.8580.760AAAStrongL7ANSCLCrs21393(G)39.671/340Recessiv1.6(1.17-1.6)0.013<0	CHRNA5	NSCLC	rs16969968(A/G)	6	3201/4736	Allelic	1.36(1.24–1.48)	$1.48  imes 10^{-11}$	13	0.329	0.707	AAA	Strong
CYP2E1NSCLCrs6k1432(AT)61290/180Alleite0.800/71-0014.90 × 10 <sup>-1</sup> 00.8681.000AAAStrongERC1NSCLCrs1615(CT)3780/810Alleite0.680/58-0801.91×10 <sup>-5</sup> 00.8000.070AAAStrongPGFR4NSCLCrs3185X(AC)4985/120Alleite125(11-137)9.08×10 <sup>-6</sup> 00.8000.734AAAStrongHYKKNSCLCrs231934(GA)40154/2404Alleite125(11-1404.63×10 <sup>-4</sup> 00.8180.734AAAStrongITATNSCLCrs279134(GA)42002/490Alleite126(11-1404.63×10 <sup>-4</sup> 00.8180.734AAAStrongTIATANSCLCrs279134(GA)3780/988Recessiv127(12-265)0.013310.230.248ABAModeratTIATANSCLCrs213245(TT)3967/340Recessiv126(11-7.18)0.010.80.430.20BAAModeratTYPE1Alleite16913432(TT)690/1809Recessiv126(11-7.18)0.010.40.80.200.430.200.430.40 <th< td=""><td>CLPTM1L</td><td>NSCLC</td><td>rs402710(T/C)</td><td>6</td><td>2940/4040</td><td>Allelic</td><td>0.85(0.79-0.91)</td><td><math>1.13 imes10^{-5}</math></td><td>0</td><td>0.666</td><td>1.000</td><td>AAA</td><td>Strong</td></th<>	CLPTM1L	NSCLC	rs402710(T/C)	6	2940/4040	Allelic	0.85(0.79-0.91)	$1.13 imes10^{-5}$	0	0.666	1.000	AAA	Strong
ERCCNSCLCrs11615(C7)3780/81Alleic0.680(8.80.81)10.1 × 10-3130.500.50AAAStrongGFR4NSCLCrs35185(A/G)3985/1230Alleic1.25(1.13-13)90.8 × 10-6000.800.901.00AAAStrongMIR146ANSCLCrs931794(G/A)41548/424Alleic1.25(1.13-13)90.8 × 10-6000.800.734AAAStrongMIR146ANSCLCrs931794(G/A)41548/424Alleic1.25(1.13-13)90.8 × 10-6000.8180.734AAAStrongMIR146ANSCLCrs23098(A/G)4200/2490Alleic1.26(1.13-14)4.63 × 10-700.8180.734AAAStrongTERTNSCLCrs1093796(T/C)3357/1440Alleic1.30(1.9-142)2.59 × 10-7000.8180.734AAAStrongTPAGNSCLCrs1093796(T/C)3357/1440Alleic1.30(1.29-17)0.91010.8180.734AAAStrongTPAGNSCLCrs21324(T)30.71440Recessive1.26(1.29-17)1.69 × 10-700.8180.7068.43AloeAloeCP12E1ADrs61333(C/C)12124/178Dominat1.50(1.29-17)1.69 × 10-7000.6440.40ASStrongTPAGADrs614332(A/T)650/180Cecssive1.20(1.0-1300.0110 <td>CYP2E1</td> <td>NSCLC</td> <td>rs6413432(A/T)</td> <td>6</td> <td>1290/1809</td> <td>Allelic</td> <td>0.80(0.71-0.91)</td> <td><math>4.90 imes10^{-4}</math></td> <td>0</td> <td>0.868</td> <td>1.000</td> <td>AAA</td> <td>Strong</td>	CYP2E1	NSCLC	rs6413432(A/T)	6	1290/1809	Allelic	0.80(0.71-0.91)	$4.90 imes10^{-4}$	0	0.868	1.000	AAA	Strong
FGFR4NSCLCrs31585(A/G)398/1200Alleic0.76(0.60)1.97 × 10°01.0001.000AAAStoragHYKNSCLCrs931794(G/A)41548/2440Alleic1.25(1.1-1.4G)4.08 × 10°00.800.734AAAStoragMIR146ANSCLCrs2910164(C)G4800104Alleic1.28(1.1-1.4G)4.08 × 10°00.810.734AAAStoragTERTNSCLCrs291084(G)40.2002490Alleic1.28(1.1-1.4G)4.04 × 10°00.810.734AAAStoragTERTNSCLCrs273913(A/G)39700.98Recsive1.27(1.1-2.65)0.113310.230.291.80AAAStoragTFANSCLCrs1739705(T)C3387/142Netco1.28(1.1-1.81)0.01000.831.00AABModerateTFANSCLCrs1739705(T)C3374/14278Dirain1.50(1.2-1.75)1.89 × 10°00.831.00AAAStoragTCTCNSCLCrs1313245(T)31.7441278Dirain1.50(1.2-1.75)1.89 × 10°00.830.200.400.40AModerateTP30ADrs104323(C)230030141.411.40(1.2-1.50)1.89 × 10°00.830.401.40NoTP31ADrs104323(C)230020.21.201.89 × 10°01	ERCC1	NSCLC	rs11615(C/T)	3	780/811	Allelic	0.68(0.58-0.81)	$1.01 \times 10^{-5}$	13	0.316	0.296	AAA	Strong
HYKKNSCLCrs919(G/A)41548/264Allelic1.25(1.1.3.1)9.08 × 0.1"0.00.080.74AAAStrongMIR1edNSCLCrs291016(C/G)4800194Allelic1.20(1.1-1.4)4.63 × 10"0.00.010.130.73AAAStrongTERTNSCLCrs275913(A/G)370098Recessive1.72(1.1-2.65)0.101310.250.20BBBModerateTP63NSCLCrs1093745(T/C)33587/844Allelic0.870.82-0.029.91 × 10"0.0.830.00AAAModerateXPC1NSCLCrs1093745(T/C)39.6711340Recessive1.46(1.17-1.81)0.010.0.830.02BAAModerateXPC2NSCLCrs215245(T/T)39.714140Dominant1.50(2.9-1.75)1.89 × 10"0.0.830.24BAAModerateCYP2E1ADrs613432(AT)69.7141278Dominant1.50(1.2-1.55)1.91 × 10"0.010.40.40.4ModerateCYP2E1ADrs613432(AT)69.7144278Allelic1.26(1.1-1.81)0.010.0 <td>FGFR4</td> <td>NSCLC</td> <td>rs351855(A/G)</td> <td>3</td> <td>985/1230</td> <td>Allelic</td> <td>0.76(0.68-0.86)</td> <td><math>1.97  imes 10^{-5}</math></td> <td>0</td> <td>0.590</td> <td>1.000</td> <td>AAA</td> <td>Strong</td>	FGFR4	NSCLC	rs351855(A/G)	3	985/1230	Allelic	0.76(0.68-0.86)	$1.97  imes 10^{-5}$	0	0.590	1.000	AAA	Strong
MIR1460         NSCLC         rs210164(C/G)         4         8001094         Allelic         1.28(1.11-46)         4.58 10^-1         0         0.31         0.31         0.34         AAA         Strong           TER         NSCLC         rs273608(A/G)         4         2002/490         Alleic         1.30(1.11-1.40)         2.59×10 <sup>-7</sup> 0         0.818         0.734         AAA         Strong           ILTA         NSCLC         rs275913(A/G)         3         780/984         Alleic         0.72(1.12-L50)         0.13         3         0.755         1.00         AAA         Moderat           TPG3         NSCLC         rs10397405(T/C)         3         537/844         Alleic         0.70(2.0-25)         0.91         0.0         0.83         0.20         BAA         Moderat           XPCC1         NSCLC         rs313245(C/T)         6         50/1809         Alleic         1.40(1.17-L13)         0.01         0.0         0.83         0.20         BAA         Strong           QP21         AD         rs41332(C/T)         6         50/1809         Alleic         1.20(1.1-L3)         0.01         0.0         0.83         0.24         AAA         Strong           QP21         AD <td>НҮКК</td> <td>NSCLC</td> <td>rs931794(G/A)</td> <td>4</td> <td>1548/2464</td> <td>Allelic</td> <td>1.25(1.13-1.37)</td> <td><math>9.08 \times 10^{-6}</math></td> <td>0</td> <td>0.880</td> <td>0.734</td> <td>AAA</td> <td>Strong</td>	НҮКК	NSCLC	rs931794(G/A)	4	1548/2464	Allelic	1.25(1.13-1.37)	$9.08 \times 10^{-6}$	0	0.880	0.734	AAA	Strong
TERTNSCLCrs2736098(A/G)42002/2490Allelic1.30(1.19-1.42)2.59 × 10 <sup>-9</sup> 0.0.8180.734AAAStrongIL17ANSCLCrs275913(A/G)3780/998Recessive1.72(1.12-2.65)0.013310.2350.906BBBModerateTP63NSCLCrs10937405(T/G)33587/848Allelic0.87(0.82-0.92)9.1 × 10 <sup>-7</sup> 00.9551.000ABAModerateXPCNSCLCrs213245(C/T)3744/178Dominat1.50(1.29-1.75)1.89 × 10 <sup>-7</sup> 00.6880.296BAAModerateCYP2E1ADrs01333(G/C)12300/867Recessive1.25(1.0-1.43)0.01100.6440.402AAAStrongerOGGADrs02333(G/C)12300/867Recessive1.20(1.0-1.43)0.01100.8160.404StrongerTPS1ADrs105233(G/C)12350/882Recessive1.20(1.0-1.43)0.014300.418AAAStrongerTPS3ADrs105233(G/C)12350/882Recessive1.20(1.0-1.43)0.014300.418AAAStrongerTPS4ADrs105293(G/G)12350/882Recessive1.20(1.0-1.43)0.014300.2140.434AAAStrongerTPS4ADrs105293(G/G)12350/882Recessive1.20(1.0-1.43)0.014300.2140.434AAAStronger	MIR146A	NSCLC	rs2910164(C/G)	4	880/1094	Allelic	1.28(1.11-1.46)	$4.63  imes 10^{-4}$	0	0.391	0.734	AAA	Strong
IL17ANSCLCrs2275913(A/G)3780/998Recessive1.72(1.12–2.65)0.013310.2350.296BBBModerateTP63NSCLCrs10937405(T/G)33587/8484Allelic0.87(0.82-0.92)9.91 × 10 <sup>-7</sup> 00.5951.000AABModerateXPCNSCLCrs2113245(C/T)397/1340Recessive1.46(1.17-1.81)0.00100.6830.296BAAModerateCYP2E1ADrs101233(G/T)6500/1809Allelic0.79(0.66-0.95)0.01100.6440.707AAAStrongeOGIADrs105213(G/G)123603/6872Recessive1.25(1.10-1.43)0.001200.4640.40StrongeStrongeTP33ADrs105220(G/G)223603/6822Recessive1.20(1.26-1.54)407 × 10 <sup>-11</sup> 00.8910.308AAAStrongeCHRNA5ADrs105202(G/G)22350/4822Recessive1.20(1.26-1.54)407 × 10 <sup>-11</sup> 00.8143.40NoderateLT73ADrs105202(G/G)22350/4822Recessive1.20(1.26-1.54)407 × 10 <sup>-11</sup> 00.8143.40NoderateLT74ADrs1045202(G/G)22350/4822Recessive1.20(1.26-1.54)407 × 10 <sup>-10</sup> 0.311.414.40ModerateLT74ADrs1391(C/A)3469/98Recessive1.84(1.11-3.06)0.018360.211.000 <t< td=""><td>TERT</td><td>NSCLC</td><td>rs2736098(A/G)</td><td>4</td><td>2002/2490</td><td>Allelic</td><td>1.30(1.19–1.42)</td><td><math>2.59 \times 10^{-9}</math></td><td>0</td><td>0.818</td><td>0.734</td><td>AAA</td><td>Strong</td></t<>	TERT	NSCLC	rs2736098(A/G)	4	2002/2490	Allelic	1.30(1.19–1.42)	$2.59 \times 10^{-9}$	0	0.818	0.734	AAA	Strong
TP63NSCLCrs10937405(T/C)33587/848Allelic0.87(0.82-0.2)9.91 × 10 <sup>-7</sup> 00.5951.000AABModerateXPCNSCLC\$\fr11'(115)'0Recessive1.46(1.17-1.81)0.00100.4831.000BAAModerateXRCC1NSCLCrs213245(CT)3174/2178Dominat1.50(1.29-1.75)1.89 × 10 <sup>-7</sup> 00.6430.206BAAModerateCYP2E1ADrs614332(AT)6500/1809Alleic0.70(0.66-0.59)0.01100.6440.707AAAStrongGGG1ADrs02308(AG)41214/240Alleic1.20(1.26-1.54)4.97 × 10 <sup>-11</sup> 00.810.308AAAStrongTP53ADrs02308(AG)41214/240Alleic1.20(1.05-1.38)0.008160.14AAAStrongTP53ADrs10452C/GD2350/687Recessive1.20(1.05-1.38)0.008160.14AAAStrongTP53ADrs10452C/GD2350/4822Recessive1.20(1.05-1.38)0.013.00.140.30AAAStrongTP53ADrs10452C/GD2350/4822Recessive1.20(1.05-1.38)0.013.00.140.30AAAModerateTP53ADrs10452C/GD2350/482Recessive1.20(1.05-1.58)0.0183.00.140.013.0AAAModerateLT74AD <td>IL17A</td> <td>NSCLC</td> <td>rs2275913(A/G)</td> <td>3</td> <td>780/998</td> <td>Recessive</td> <td>1.72(1.12-2.65)</td> <td>0.013</td> <td>31</td> <td>0.235</td> <td>0.296</td> <td>BBB</td> <td>Moderate</td>	IL17A	NSCLC	rs2275913(A/G)	3	780/998	Recessive	1.72(1.12-2.65)	0.013	31	0.235	0.296	BBB	Moderate
XPCNSCLCPAT/+ (ins) noins)39671340Recesive1.46(1.17-1.81)0.0100.4831.000BAAModerateXRCC1NSCLCrs213245(7/T)3744/2178Dominati1.50(1.29-1.75)1.89 × 10^-700.6830.203BAAModerateCYP221ADrs61332(A/T)650/1809Alleic0.79(0.60-0.95)0.1100.6440.707AAAStrongOGG1ADrs105213(G/C)12303/677Recesive1.25(1.01-1.43)0.0100.840.408AlongStrongTERTADrs10523(G/C)2304/822Recesive1.20(1.05-1.38)0.011.00.140.43AAAStrongTP53ADrs104522(C/G)2350/8820Recesive1.20(1.05-1.38)0.013.00.140.43AAAStrongCHRNA5ADrs104522(C/G)2350/8820Recesive1.30(1.0-1.000.160.160.14AAAModerateFRC2ADrs1381(C/A)41.507/284Aleic1.30(1.0-1.000.160.160.14AAAModerateIL17AADrs275913(A/G)346/998Recesive1.81(1.1-3.000.184.00.810.10AAAModerateTP3GADrs213245(C/T)3459/98Recesive1.81(1.1-3.000.184.00.160.14AAAModerateTP4ADrs2	TP63	NSCLC	rs10937405(T/C)	3	3587/8484	Allelic	0.87(0.82-0.92)	9.91 × 10 <sup>-7</sup>	0	0.595	1.000	AAB	Moderate
XRCC1NSCLCNS213245(CT)S174/178Dominet150(129-17)189×10 <sup>-7</sup> 00.830.941AMModerateCYP2E1ADrs611332(AT)650/180Alcle70/06-050011000.640.70AAStongOGG1ADrs105213(GC)120303/677Recsive12(1/1-014)0101100.810.810.84AAStongTERTADrs103203(CD21304/822Recsive1.2(1/1-014)0.910.810.810.81AAStongTP3AADrs103203(CD21304/822Recsive1.2(1/1-014)0.910.810.810.81AAStongTP3AADrs103203(CD21304/822Recsive1.2(1/1-014)0.913.90.210.43AAStongTP3AADrs103203(CD464/120Recsive1.2(1/1-014)0.910.90.810.41AAModerateTP3AADrs1318(CA464/120Recsive1.2(1/1-014)0.910.90	XPC	NSCLC	PAT-/+(ins/ non-ins)	3	967/1340	Recessive	1.46(1.17-1.81)	0.001	0	0.483	1.000	BAA	Moderate
CYP2E1ADsfe413432(AT)650/180Alleia0.70(6.6-0.5)0.0100.640.70AAAStrongOGG1ADs1052133(GC)12363/6677Recsive12(1)-1.430.01200.2460.45AAAStrongTERTADs73698(AG)4121/2400Alleia14(1)-61.43497×10 <sup>-11</sup> 00.890.890.40StrongTP53ADs104522(C)2350/822Recsive1.2(1)-1.430.0130.240.43AAAStrongCHRNA5ADs169986(AG)4507/834Alleia1.3(1)-1.430.0130.240.34AAAMoreateFRC2ADs1311(CA)464/1230Diniant1.5(1)-61.400.0130.210.34AAAMoreateIL7AADs729714(GT)664/1230Diniant1.5(1)-61.400.0130.211.00BABMoreateIL7AADs229714(GT)664/1230Diniant1.5(1)-61.400.0160.211.00BABMoreateIL7AADs229714(GT)61.71/408Recsive1.26(1)-61.400.0160.01 <td< td=""><td>XRCC1</td><td>NSCLC</td><td>rs3213245(C/T)</td><td>3</td><td>1744/2178</td><td>Dominant</td><td>1.50(1.29-1.75)</td><td><math>1.89  imes 10^{-7}</math></td><td>0</td><td>0.683</td><td>0.296</td><td>BAA</td><td>Moderate</td></td<>	XRCC1	NSCLC	rs3213245(C/T)	3	1744/2178	Dominant	1.50(1.29-1.75)	$1.89  imes 10^{-7}$	0	0.683	0.296	BAA	Moderate
OGGIADinfo2133(GC)12303/6677Recesive125(1.0-1.4)0.01200.240.945AAStrongTERTADr237098(AG)4214/2490Aleic1.40(1.26-1.54)497×10 <sup>-11</sup> 0.0.8910.308AAStrongTP53ADr14252C(C)2504/822Recesive1.20(1.05-1.38)0.011.60.410.41AAStrongCHRNA5ADr169998(AG)4507/234Aleic1.37(1.4-1.64)0.013.0.410.34AGModerateERCC2ADr3181C/AD464/1230Diniant1.35(1.0-1.70)0.130.40.450.44ModerateIL17AADr227931A(G)464/1230Diniant1.35(1.0-1.00)0.140.41.00BAModerateMDM2ADr227974G(T)6114/4030Recesive1.84(1.1-3.00)0.186.00.141.00BAModerateTP63ADr227974G(T)6114/4030Recesive1.84(1.1-3.00)0.186.00.141.00BAModerateTP64ADr227974G(T)6114/4030Recesive1.84(1.1-3.00)0.186.00.180.161.001.00AGAGTP64ADr227974G(T)6114/4030Recesive1.84(1.1-3.00)0.181.01.00AG1.00AGAGAGTP64ADr229974G(T)<	CYP2E1	AD	rs6413432(A/T)	6	500/1809	Allelic	0.79(0.66-0.95)	0.011	0	0.664	0.707	AAA	Strong
TERTADrs236098(A/G)41214/2490Alelic1.40(1.26-1.54)9.7×10 <sup>-11</sup> 0.0.8910.308AAAStrongTP53ADri104252(C/G)23504/822Recssive1.20(1.05-1.38)0.008160.4530.143AAAStrongCHRNA5ADri1696988(A/G)41507/234Alelic1.37(1.4164)0.01330.140.734ABAModerateERC2ADri3181(C/A)466/1230Domiant1.35(1.06-1.70)0.130.60.734BAAModerateIL7AADrs27591A(G)364/930Domiant1.35(1.06-1.70)0.130.60.734BACModerateMDM2ADrs2759744(G/T)464/930Recssive1.84(1.1-3.00)0.186.00.8980.707ABAModerateTP63ADrs213245(C/T)3158/848Aleic0.820,75-0.002.91×1.700.8.980.804AGAModerateTVP1A1SCCrs646903(C/T)3101/959Aleic1.561.29-1.803.72×1.700.0.753.44ModerateGYP2E1SCCrs646903(C/T)3102/1.959Aleic1.67(1.6.6.5-88)3.98×1.040.010.10AAAModerateGYP2E1SNCRsnokerssnokerssnokerssnokerssnokerssnokerssnokers3.04Aleic1.01(1.6.9.6.50.803.98×1.41.00A.00A.00 <t< td=""><td>OGG1</td><td>AD</td><td>rs1052133(G/C)</td><td>12</td><td>3603/6677</td><td>Recessive</td><td>1.25(1.10-1.43)</td><td>0.001</td><td>20</td><td>0.246</td><td>0.945</td><td>AAA</td><td>Strong</td></t<>	OGG1	AD	rs1052133(G/C)	12	3603/6677	Recessive	1.25(1.10-1.43)	0.001	20	0.246	0.945	AAA	Strong
TP53ADrs104252(C/G)223504/882Recesive1.20(1.05-1.38)0.008160.2450.143AAAStrongCHRNA5ADrs169696(A/G)41507/2834Allcic1.37(1.4-1.64)0.01330.2140.734ABAModerateERCC2ADrs1318(C/A)464/1230Dominant1.35(1.06-1.70)0.01300.6350.734BAAModerateIL17AADrs275913(A/G)364/998Recesive1.84(1.1-3.06)0.018360.2141.000BBBModerateMDM2ADrs27974(G/T)61714/4083Recesive1.28(1.04-1.65)0.018640.9880.298	TERT	AD	rs2736098(A/G)	4	1214/2490	Allelic	1.40(1.26-1.54)	$4.97\times10^{-11}$	0	0.891	0.308	AAA	Strong
CHRNA5ADrs16969968(AG)41507/2834Allelic1.37(1.14-1.64)0.001330.2140.734ABAModerateERCC2ADrs1318(C/A)4664/1230Dominant1.35(1.06-1.70)0.01300.6350.734BAAModerateIL17AADrs2275913(AG)3669/988Recesive1.84(1.11-3.06)0.018360.2111.000BBBModerateMDM2ADrs2275913(AG)30.714/4083Recesive1.28(1.04-1.56)0.018460.9880.207ABAModerateTP63ADrs1093745(T/C)3158/8484Alleic0.82(0.75-0.90)2.91 × 10^{-5}00.880.2980.298ModerateTP63ADrs1313245(T)3860/2178Dominant1.55(1.29-1.87)4.72 × 10^{-6}00.880.298BAAModerateTYP1A1SCCrs413432(AT)671/1809Alleic1.45(1.26-1.67)3.77 × 10^{-7}210.2150.232AAAStorgerGYP2E1SCCrs613432(AT)671/1809Alleic1.30(1.02-1.64)0.303430.1741.000BAAModerateGYP2E1smokersrs646903(CT)71034/1087Alleic1.30(1.02-1.64)0.303430.1741.000AAAStorgerGYP2E1smokersrs613432(AT)30.39/1087Alleic1.30(1.02-1.64)0.303460.380	TP53	AD	rs1042522(C/G)	22	3504/8822	Recessive	1.20(1.05-1.38)	0.008	16	0.245	0.143	AAA	Strong
ERCC2ADrs1311(C/A)4664/1230Dominant1.35(1.06-1.70)0.01300.6350.734BAAModerateIL17AADrs227513(A/G)3469/98Recessive1.84(1.11-3.06)0.018360.2111.000BBBModerateMDM2ADrs227974(G/T)61714/083Recessive1.28(1.04-1.56)0.018460.9880.296ABAModerateTP63ADrs1037405(T/C)31158/848Alleic0.82(0.75-0.90)2.91 × 10^{-5}00.8980.296AABModerateXRC1ADrs313245(C/T)3860/2178Dominant1.55(1.29-1.87)4.72 × 10^{-6}00.7580.296BAAModerateCYP1A1SCCrs464903(C/T)171021/3959Alleic1.45(1.26-1.67)3.77 × 10^{-7}210.2150.232AAAStrongCYP2A1SCCrs41432(A/T)6715/1809Alleic0.76(0.55-0.88)3.98 × 10^{-4}00.910.260AAAStrongCYP2A1smokersrs466903(C/T)6103/1087Alleic1.30(1.02-1.64)0.033460.8080.230BAAModerateCYP2A4smokersrs464903(C/T)3133/848Alleic0.71(0.59-0.85)2.30 × 10^{-4}130.301.000BAAModerateCYP2A5smokersrs464903(C/T)3133/848Alleic0.71(0.59-0.85)2.30 × 10^{-4} <t< td=""><td>CHRNA5</td><td>AD</td><td>rs16969968(A/G)</td><td>4</td><td>1507/2834</td><td>Allelic</td><td>1.37(1.14-1.64)</td><td>0.001</td><td>33</td><td>0.214</td><td>0.734</td><td>ABA</td><td>Moderate</td></t<>	CHRNA5	AD	rs16969968(A/G)	4	1507/2834	Allelic	1.37(1.14-1.64)	0.001	33	0.214	0.734	ABA	Moderate
IL17AADs227591A(A)3469/98Recessive1.84(1.1-3.06)0.018360.2111.000BBBModerateMDM2ADrs279744(G/T)6714/403Recessive128(1.04-1.56)0.18460.080.707ABAModerateTP63ADrs10937405(T/C)3158/848Alleic0.82(0.75-0.90)291×10 <sup>-5</sup> 00.8980.296AAAModerateXRCC1ADrs213245(C/T)3860/2178Dominant1.55(1.29-1.87)4.72×10 <sup>-6</sup> 00.7580.296BAAModerateCYP1A1SCCrs464903(C/T)171021/3959Alleic1.45(1.26-1.67)3.77×10 <sup>-7</sup> 210.2150.232AAAStorageCYP2A1SCCrs464903(C/T)6715/1809Alleic0.76(0.65-0.88)3.98×10 <sup>-4</sup> 00.141.000BAAStorageAPEX1smokersrs176094(A/C)365/647Alleic1.37(1.1-6.991.033450.141.000ABAModerateCYP1A1smokersrs46693(C/T)30.33/1.02Alleic0.301.023.034.00.3304.00.3304.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.3014.00.	ERCC2	AD	rs13181(C/A)	4	664/1230	Dominant	1.35(1.06-1.70)	0.013	0	0.635	0.734	BAA	Moderate
MDM2ADrs2279744(G/T)61714/403Recessive1.28(1.04-1.56)0.018460.0980.707ABAModerateTP63ADrs10937405(T/C)3158/848Alleic0.82(0.75-0.90)2.91 × 10^-500.8980.296AABModerateXRCC1ADrs3213245(C/T)3860/2178Dominati1.55(1.29-1.87)4.72 × 10^-600.750.296BAAModerateCYP1A1SCCrs464903(C/T)171021/3959Alleic1.45(1.26-1.67)3.77 × 10^-7210.2150.232AAAStrongCYP2E1SCCrs641332(A/T)6715/1809Alleic0.76(0.65-0.88)3.98 × 10^-400.9110.260AAAStrongAPEX1smokersrs176094(A/C)3655/647Alleic1.37(1.1-1.69)0.033460.0880.230BAAModerateCYP1A1smokersrs466903(C/T)71034/1087Alleic1.30(1.02-1.64)0.033460.0880.230BAAModerateCYP1A1smokersrs464903(C/T)71034/1087Alleic0.71(0.59-0.85)2.30 × 10^-4130.1031.600BAAModerateCYP2A6smokersrs464903(C/T)396/791Alleic0.71(0.59-0.85)2.30 × 10^-4130.301.600BAAModerateCYP2A6smokersrs41332(A/T)376/791Alleic0.75(0.63-0.90)0.020 <t< td=""><td>IL17A</td><td>AD</td><td>rs2275913(A/G)</td><td>3</td><td>469/998</td><td>Recessive</td><td>1.84(1.11-3.06)</td><td>0.018</td><td>36</td><td>0.211</td><td>1.000</td><td>BBB</td><td>Moderate</td></t<>	IL17A	AD	rs2275913(A/G)	3	469/998	Recessive	1.84(1.11-3.06)	0.018	36	0.211	1.000	BBB	Moderate
TP63ADrs10937405(T/C)31158/848Alleic $0.82(0.75-0.90)$ $2.91 \times 10^{-5}$ 0 $0.898$ $0.296$ AABModerateXRC1ADrs213245(C/T)3860/178Dominan $1.55(1.29-1.87)$ $4.72 \times 10^{-6}$ 0 $0.758$ $0.296$ BAAModerateCYP1A1SCCrs646903(C/T)171021/3959Alleic $1.45(1.26-1.67)$ $3.77 \times 10^{-7}$ $21$ $0.215$ $0.232$ AAAStrongCYP2A1SCCrs641342(A/T)6715/1809Alleic $0.76(0.65-0.88)$ $3.98 \times 10^{-4}$ $0.21$ $0.260$ AAAStrongAPEX1smokersrs176094(A/C)3655/647Alleic $1.37(1.1-1.69)$ $0.03.$ $4.2$ $0.30.$ $A.28$ $A.28$ ModerateCYP1A1smokersrs464903(C/T)7 $0.33/1087$ Alleic $0.31(0.2-1.64)$ $0.33.$ $4.5$ $0.208$ $B.A4$ ModerateCYP2A6smokersrs41432(A/T)3 $0.39/1488$ Alleic $0.71(0.59-0.85)$ $2.30 \times 10^{-4}$ $1.30.$ $0.30.$ $4.5$ $0.30.$ $B.45$ $0.208$ $B.A4$ ModerateCYP2A6smokersrs41332(A/T)3 $96/791$ Alleic $0.71(0.59-0.85)$ $2.30 \times 10^{-4}$ $1.30.$ $0.30.$ $1.40.$ $0.30.$ $0.20.$ $B.A4$ ModerateCYP2A6smokersrs41332(A/T)3 $96/791$ Alleic $0.71(0.59-0.85)$ $0.02.$ $2.0.$ $0.30.$ $0.20.$ <td>MDM2</td> <td>AD</td> <td>rs2279744(G/T)</td> <td>6</td> <td>1714/4083</td> <td>Recessive</td> <td>1.28(1.04-1.56)</td> <td>0.018</td> <td>46</td> <td>0.098</td> <td>0.707</td> <td>ABA</td> <td>Moderate</td>	MDM2	AD	rs2279744(G/T)	6	1714/4083	Recessive	1.28(1.04-1.56)	0.018	46	0.098	0.707	ABA	Moderate
XRCC1       AD       rs213245(C/T)       3       860/2178       Dominant $1.55(1.29-1.87)$ $4.72 \times 10^{-6}$ 0 $0.788$ $0.296$ BAA       Moderate         CYP1A1       SCC       rs464903(C/T)       17       1021/3959       Alleic $145(1.26-1.67)$ $3.77 \times 10^{-7}$ 21 $0.215$ $0.232$ AAA       Strong         CYP2A1       SCC       rs6413432(A/T)       6       715/1809       Alleic $0.76(0.65-0.88)$ $3.98 \times 10^{-4}$ 0 $0.10$ $0.260$ AAA       Strong         APEX1       smokers       rs176094(A/C)       3 $655/647$ Alleic $1.37(1.11-1.69)$ $0.03$ 46 $0.280$ AAA       Strong         CYP1A1       smokers       rs4646903(C/T)       7 $1034/1087$ Alleic $1.37(1.1-1.69)$ $0.03$ 46 $0.808$ $0.280$ BAA       Moderate         CYP2A5       smokers       rs4646903(C/T)       7 $1034/1087$ Alleic $0.71(0.59-0.85)$ $2.30 \times 10^{-4}$ $130$ $0.30$ BA $0.208$ BAA       Moderate         CYP2A6       smokers       rs6413432(A/T)       3	TP63	AD	rs10937405(T/C)	3	1158/8484	Allelic	0.82(0.75-0.90)	$2.91\times10^{-5}$	0	0.898	0.296	AAB	Moderate
CYP1A1         SCC         rs4646903(C/T)         17         1021/3959         Allelic         1.45(1.26-1.67) $3.77 \times 10^{-7}$ 21         0.215         0.232         AAA         Strong           CYP2A1         SCC         rs6413432(A/T)         6         715/1809         Alleic         0.76(0.65-0.88) $3.98 \times 10^{-4}$ 0         0.911         0.260         AAA         Strong           APEX1         smokers         rs176094(A/C)         3         655/647         Alleic         1.37(1.11-1.69)         0.003         43         0.174         1.000         ABA         Moderate           CYP1A1         smokers         rs4646903(C/T)         7         1034/1087         Alleic         1.30(1.02-1.64)         0.033         46         0.88         0.230         BBA         Moderate           CYP2A6         smokers         rs4046903(C/T)         7         1339/848         Alleic         0.71(0.59-0.85)         2.30 $\times 10^{-4}$ 13         0.30         BAA         Moderate           CYP2A6         smokers         rs6413432(A/T)         3         796/791         Alleic         0.75(0.63-0.90)         0.002         2         0.360         0.296         BAA         Moderate	XRCC1	AD	rs3213245(C/T)	3	860/2178	Dominant	1.55(1.29–1.87)	$4.72\times10^{-6}$	0	0.758	0.296	BAA	Moderate
CYP2E1         SCC         rs6413432(A/T)         6         715/1809         Alleic $0.76(0.65-0.88)$ $3.98 \times 10^{-4}$ 0 $0.911$ $0.260$ AAA         Strong           APEX1         smokers         rs176094(A/C)         3 $655/647$ Alleic $1.37(1.1-1.69)$ $0.03$ 43 $0.174$ $1.000$ ABA         Moderate           CYP1A1         smokers         rs4646903(C/T)         7 $1034/1087$ Alleic $1.30(1.02-1.64)$ $0.03$ 46 $0.88$ $0.230$ BBA         Moderate           CYP2A6         smokers         *4/non*4         3 $1339/848$ Alleic $0.71(0.59-0.85)$ $2.30 \times 10^{-4}$ 13 $0.40$ BAA         Moderate           CYP2A6         smokers         rs641332(A/T)         3 $796/71$ Alleic $0.71(0.59-0.85)$ $2.30 \times 10^{-4}$ 13 $0.40$ BAA         Moderate           CYP2A6         smokers         rs641332(A/T)         3 $796/71$ Alleic $0.75(0.63-0.90)$ $0.02$ $2$ $0.360$ $0.260$ BAA         Moderate <tr< td=""><td>CYP1A1</td><td>SCC</td><td>rs4646903(C/T)</td><td>17</td><td>1021/3959</td><td>Allelic</td><td>1.45(1.26-1.67)</td><td><math>3.77  imes 10^{-7}</math></td><td>21</td><td>0.215</td><td>0.232</td><td>AAA</td><td>Strong</td></tr<>	CYP1A1	SCC	rs4646903(C/T)	17	1021/3959	Allelic	1.45(1.26-1.67)	$3.77  imes 10^{-7}$	21	0.215	0.232	AAA	Strong
APEX1         smokers         rs1760944(A/C)         3         655/647         Allelic         1.37(1.1-1.69)         0.003         43         0.174         1.000         ABA         Moderate           CYP1A1         smokers         rs4646903(C/T)         7         1034/1087         Allelic         1.30(1.02-1.64)         0.033         46         0.088         0.230         BBA         Moderate           CYP2A6         smokers         *4/non*4         3         1339/848         Allelic         0.71(0.59-0.85)         2.30 × 10 <sup>-4</sup> 13         0.319         1.000         BAA         Moderate           CYP2A1         smokers         rs6413432(A/T)         3         796/791         Allelic         0.75(0.63-0.90)         0.002         2         0.360         0.296         BAA         Moderate           Continued	CYP2E1	SCC	rs6413432(A/T)	6	715/1809	Allelic	0.76(0.65-0.88)	$3.98  imes 10^{-4}$	0	0.911	0.260	AAA	Strong
CYP1A1         smokers         rs4646903(C/T)         7         1034/1087         Allelic         1.30(1.02-1.64)         0.033         46         0.088         0.230         BBA<         Moderate           CYP2A6         smokers         *4/non*4         3         1339/848         Allelic         0.71(0.59-0.85)         2.30×10 <sup>-4</sup> 13         0.319         1.000         BAA         Moderate           CYP2E1         smokers         rs6413432(A/T)         3         796/791         Allelic         0.75(0.63-0.90)         0.002         2         0.360         0.296         BAA         Moderate           Continued	APEX1	smokers	rs1760944(A/C)	3	655/647	Allelic	1.37(1.11-1.69)	0.003	43	0.174	1.000	ABA	Moderate
CYP2A6         smokers         *4/non*4         3         1339/848         Allelic         0.71(0.59-0.85)         2.30 × 10 <sup>-4</sup> 13         0.319         1.000         BAA         Moderate           CYP2E1         smokers         rs6413432(A/T)         3         796/791         Allelic         0.75(0.63-0.90)         0.002         2         0.360         0.296         BAA         Moderate           Continued <td>CYP1A1</td> <td>smokers</td> <td>rs4646903(C/T)</td> <td>7</td> <td>1034/1087</td> <td>Allelic</td> <td>1.30(1.02-1.64)</td> <td>0.033</td> <td>46</td> <td>0.088</td> <td>0.230</td> <td>BBA</td> <td>Moderate</td>	CYP1A1	smokers	rs4646903(C/T)	7	1034/1087	Allelic	1.30(1.02-1.64)	0.033	46	0.088	0.230	BBA	Moderate
CYP2E1         smokers         rs6413432(A/T)         3         796/791         Allelic         0.75(0.63-0.90)         0.002         2         0.360         0.296         BAA         Moderate	CYP2A6	smokers	*4/non*4	3	1339/848	Allelic	0.71(0.59-0.85)	$2.30 imes10^{-4}$	13	0.319	1.000	BAA	Moderate
Continued	CYP2E1	smokers	rs6413432(A/T)	3	796/791	Allelic	0.75(0.63-0.90)	0.002	2	0.360	0.296	BAA	Moderate
	Continued	•		•		•			-			•	

			Number e	valuated	Lung-cancer risk meta-analysis				Heterogeneity		Venice	
Gene	Subgroup	Variants*	Studies	Cases/ Controls	Genetic models	OR(95%CI)	p value	I <sup>2</sup> (%)	P <sub>Q</sub> II	Begg P	criteria grades∫	Credibility of evidence <sup>§</sup>
CYP2E1	smokers	rs2031920(T/C)	3	1064/1220	Allelic	0.76(0.65-0.90)	0.001	0	0.727	0.296	BAA	Moderate
GSTP1	smokers	rs1138272(T/C)	3	924/1026	Dominant	1.63(1.28-2.08)	$9.17\times10^{-5}$	0	0.459	1.000	BAA	Moderate
NBN	smokers	rs1805794(G/C)	3	1226/1220	Recessive	0.83(0.71-0.98)	0.030	0	0.554	0.296	BAA	Moderate
ERCC1	non-smokers	rs11615(C/T)	3	731/958	Allelic	0.85(0.72-0.99)	0.042	0	0.449	1.000	AAA	Strong
CYP2E1	non-smokers	rs6413432(A/T)	5	315/560	Dominant	0.72(0.54-0.97)	0.028	0	0.959	0.806	BAA	Moderate
CYP2E1	non-smokers	rs2031920(T/C)	3	304/695	Allelic	0.70(0.54-0.90)	0.005	0	0.863	1.000	BAA	Moderate
ERCC2	non-smokers	rs13181(C/A)	3	478/469	Dominant	1.88(1.36-2.58)	$1.11  imes 10^{-4}$	0	0.550	0.296	BAA	Moderate
GSTM1	non-smokers	null/present	32	1924/4718	Allelic	1.37(1.16-1.61)	$1.60 imes10^{-4}$	41	0.009	0.212	ABA	Moderate
TP53	non-smokers	rs1042522(C/G)	11	1882/2887	Recessive	1.28(1.01-1.61)	0.040	39	0.088	0.586	ABA	Moderate
XRCC1	non-smokers	rs3213245(C/T)	3	977/1310	Dominant	1.43(1.17-1.75)	$4.56\times10^{-4}$	0	0.530	0.296	BAA	Moderate

**Table 3.** Genetic variants with significant associations with lung cancer risk in subgroup meta-analyses with strong or moderate cumulative evidence (Continued on next page). OR = odds ratio; 95%CI = 95% confidence interval. ins = insertion. del = deletion. CNV = copy number variation. SCLC = small cell lung cancer. NSCLC = non-small cell lung cancer. AD = adenocarcinoma. SCC = squamous cell carcinoma. \*Minor alleles/major alleles (per Caucasian); major alleles were treated as reference alleles in the analyses. P value of the test for between-study heterogeneity. <sup>f</sup>Venice criteria grades are for amount of evidence, replication of the association, and protection from bias. <sup>§</sup>Credibility of evidence is categorized as "strong", "moderate", or "weak" for association with lung cancer risk; one association with strong evidence for a variant was not considered the bias of low OR for the presence of highly consistent results across studies enrolled in meta-analysis.

In addition, we found two SNPs with strong evidence of associations with lung cancer risk are located in miRNA gene coding regions, rs2910164 (C > G) in the seed of miR-146a-3p encoded by *MIR146A* and rs11614913 (C > T) in the mature sequence of miR-196a-3p encoded by *MIR196A2*<sup>39</sup>. Both SNPs showed significant miRNA expression differences between their alleles<sup>39,40</sup> and could affect the stability of secondary hairpin structure<sup>39</sup>. Study also showed that rs2910164 can influence the interaction between miR-146a-3p and its potential target genes, and rs11614913 can increase the affinity of miR-196a-3p for *TP53*<sup>39</sup>.

Our subgroup analyses also provided additional important details of genetic associations in specific groups. The results of subgroup meta-analyses by ethnicity supported the well-known cognition of "racial" differences in genetic effects for complex diseases including lung cancer<sup>41</sup> and indicated that some variants (eg, *APEX1* rs1130409, *CHRNA5* rs16969968, *ERCC2* rs13181, *SOD2* rs4880, and *CYP2E1* rs6413432) with strong evidence may be ethnic-specifically associated with lung cancer risk. Previous studies had demonstrated the existence of different genetic background in different histological subtypes of lung cancer<sup>15, 42</sup>. When cases were stratified according to histological types, the associations between several variants (eg, *CYP2E1* rs6413432, *OGG1* rs1052133, *TP53* rs1042522, and *CYP1A1* rs4646903) and specific subtypes of lung cancer were of strong evidence. A growing number of studies demonstrates interactions between genetic variants and smoking<sup>43, 44</sup>. Our subgroup analysis also found that some variants showed significant associations with lung cancer risk in smokers but not in non-smokers, for example *CYP1A1* rs4646903 and *GSTP1* rs1695.

As the purpose of meta-analysis is not only to reveal genetic variants significantly associated with lung cancer risk, but also to identify the variants with non-significant associations. Our study revealed that 150 variants in 98 genes had non-significant associations with lung cancer risk. However, most of these variants had weak cumulative epidemiological evidence due to the presence of insufficient statistical power (119/150) and/or strong between-study heterogeneity (73/150), and only 11(7.3%) variants had strong or moderate cumulative evidence. Our results provided important clues to further assess the main effects of these variants.

Despite a comprehensive and systematic approach was applied to the synopsis of genetic association studies in lung cancer, several limitations should be considered when interpreting our results. First, although available studies were searched widely and eligible studies were selected strictly according to the inclusion and exclusion criteria, it is possible that some studies might have been overlooked. Our studies didn't include research published in the form of abstracts or in language other than English. However, for most abstracts, we also searched and included relevant studies published with whole text and reported by the same research groups. Publication biases were not identified in most meta-analyses with significant association results. Also, the proportion of studies published in language other than English is small therefore it should not have significant influence on the main results. Second, the percentage of meta-analyses with high heterogeneity  $(I^2 > 50)$  was more than 40% for all meta-analyses with a significant result. Although subgroup analyses stratified by ethnicity, histology, and smoking status were performed to address the heterogeneity, other sources of heterogeneity could exist and are difficult to address because of limited available data. Third, although we tried to explore the consistency and difference in genetic associations between some variants and lung cancer risk across different ethnic groups, meta-analyses stratified by ethnicity were performed only for Caucasian and Asian populations. Since very few enrolled original studies were carried out in other descent populations (e.g. African descent), the available data were not sufficient to perform subgroup meta-analyses in other descent populations. Additional association studies are needed to establish in populations of other ethnic descent for these reported variants. Finally, although we conducted systematic evaluations of cumulative epidemiological evidence for variants associated with lung cancer risk, biases cannot be completely excluded in this study.

		HaploRegv	/4.1∫										PolyPhen-2 <sup>§</sup>		
variant	Gene (or near gene)	GERP conserved	Promoter histone marks	Enhancer histone marks	DNAse	Proteins bound	Motifs changed	NHGRI/ EBI GWAS hits	GRASP QTL hits	Selected eQTL hits	RefSeq genes	dbSNP functional annotation	predicted consequence on protein function	PolyPhenscore <sup>¶</sup>	
rs1760944	APEX1		24 tissues*	14 tissues*	52 tissues*	11 bound proteins			2 hits	69 hits*	OSGEP	5'UTR			
rs6495309	CHRNA3		ТНҮМ	4 tissues	ТНҮМ		7 altered		2 hits	10 hits	1.4 kb 3' of CHRNB4				
rs1126579	CXCR2		BLD	BLD			9 altered			69 hits*	CXCR2	3'UTR			
rs6413432	CYP2E1		4 tissues	IPSC			8 altered			1 hit	CYP2E1	intronic			
rs931794	НҮКК			ESDR, SKIN, BRN			4 altered		1 hit	26 hits	AGPHD1	intronic			
rs664677	ATM			BLD, FAT, LIV			4 altered			24 hits	ATM	intronic			
rs402710	CLPTM1L		4 tissues	7 tissues			5 altered	1 hit <sup>†</sup>	1 hit	1 hit	CLPTM1L	intronic			
rs4646903	CYP1A1		SKIN	LNG						8 hits	241 bp 3' of <i>CYP1A1</i>				
rs2240308	AXIN2		22 tissues*	23 tissues*	6 tissues		Smad3		2 hits	3 hits	AXIN2	missense	benign	0	
rs662	PON1	conserved	LNG*	10 tissues*					2 hits	2 hits	PON1	missense	benign	0	
rs462779	REV3L	conserved					BRCA1, Nkx3		1 hit	2 hits	REV3L	missense	benign	0	
rs1130409	APEX1		20 tissues*	23 tissues*	4 tissues		ZNF263			8 hits	APEX1	missense	benign	0	
rs16969968	CHRNA5									32 hits*	CHRNA5	missense	benign	0.045	
rs13181	ERCC2	conserved	ESDR, SKIN, SPLN	4 tissues	4 tissues			1 hit <sup>‡</sup>	3 hits	18 hits*	ERCC2	missense	benign	0	
rs4880	SOD2		24 tissues*	19 tissues*	46 tissues*	CMYC,POL2, SIN3AK20	CHD2		1 hit	29 hits*	SOD2	missense	benign	0	
rs351855	FGFR4	conserved	4 tissues	15 tissues*	LIV		5 altered		2 hits	15 hits	FGFR4	missense	probably damaging	0.998	
rs1052133	OGG1	conserved	BLD, SKIN	10 tissues*			GATA			5 hits*	OGG1	missense	benign	0.121	
rs1042522	TP53		5 tissues	9 tissues*	LNG*		9 altered		1 hit	1 hit	TP53	missense	benign	0.083	
rs2736098	TERT		10 tissues*	16 tissues*	BLD		9 altered	1 hit		1 hit*	TERT	synonymous			
rs11615	ERCC1	conserved	9 tissues	21 tissues*	4 tissues	ZNF263	EBF,Mtf1		2 hits	5 hits	ERCC1	synonymous			
rs2910164	MIR146A	conserved	4 tissues	8 tissues							MIR146A				
rs11614913	MIR196A2	conserved	13 tissues	16 tissues*	8 tissues*		HMG-IY		1 hit	6 hits	MIR196A2				

**Table 4.** Functional annotation of 22 variants associated with lung cancer risk with strong evidence using HaploReg v4.1 and PolyPhen-2. 'The gene name for the SNP, locating in a respective gene, was based on the annotation of dbSNP database (https://www.ncbi.nlm.nih.gov/snp/). The near gene name for a SNP that didn't map into a gene region but its location nearby a gene based on the annotation of dbSNP database, and we also used this nearby gene name for the SNP in our study. <sup>J</sup>HaploReg v4.1: a Web server for annotation of transcription regulation for genetic variants (http://archive.broadinstitute.org/mammals/haploreg/haploreg. php). <sup>§</sup>PolyPhen-2: a Web server for annotation of potential effects on protein structure and function for non-synonymous SNPs (http://genetics.bwh.harvard.edu/pph2/). <sup>¶</sup>The PolyPhen-2 reported a score that the calculated naive Bayes posterior probability of a given mutation being damaging ranging from 0 to 1, which was also classified as benign [0, 0.15], possibly damaging (0.15, 0.85], and probably damaging (0.85, 1], respectively. <sup>\*</sup>Including regulatory evidence in lung cancer cell lines/tissues or normal lung cell lines/tissues. <sup>†</sup>GWAS for the trait of lung cancer with a P-value at  $4.0 \times 10^{-6}$ . <sup>‡</sup>GWAS for the trait of lung cancer with a P-value at  $4.0 \times 10^{-6}$ .

.....

In summary, our comprehensive research synopsis and meta-analysis identified 22 variants in 21 genes had strong cumulative epidemiological evidence of significant associations with lung cancer risk. While, among variants without significant associations with lung cancer, seven had strong evidence. Our findings provided useful data and important references for the future studies to evaluate the genetic role in the field of lung cancer. The identification of genetic variants with robust association to lung cancer may help us to get more precise estimate of population risk stratification and potential target population for primary prevention.

#### Methods

**Selection criteria and search strategies.** All methods were in accordance with the PRISMA statement, the HuGE Review Handbook (version1.0) guiding genetic reviews specifically, and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines<sup>20–22, 45</sup>.

A study for inclusion had to meet the following four criteria: (1) it evaluated the association between a genetic polymorphism and lung cancer risk using a case-control, cohort, or a cross-sectional design in human;

(2) lung cancer cases were diagnosed by pathological and/or histological examination; (3) it was published in a peer-reviewed scientific journal or online in English; (4) it provided sufficient information of genotype and/or allelic distributions for both cases and controls. We excluded studies with a family-based design and loci with genome-wide significant ( $P < 5 \times 10^{-8}$ ) identified by GWAS since they have been replicated by many studies.

To identify all published association studies potentially eligible for inclusion in our meta-analysis, we performed a comprehensive literature search (Fig. 1). Two electronic databases (PubMed and EMBASE) were queried with the terms "lung cancer (as well as synonyms of lung cancer) AND associate\*" on or before December 31, 2014. This search yielded 41,457 publications, and then screened respectively for eligibility using the title, abstract, or full-paper, as necessary. For publications between December 31, 2014 and November 1, 2015, we searched databases (PubMed and EMBASE) monthly using the previous search terms and the additional terms of "lung cancer AND [gene/loci names identified in enrolled publications]". This second search identified 4,453 additional potential publications. Furthermore, we screened for bibliographies in reviews, published meta-analyses, and cited articles from the retrieved publications. Taken together, a total of 1,018 eligible papers were finally selected and their full-text versions were carefully reviewed for further analyses (Fig. 1).

**Data management and abstraction.** When multiple publications used the same or overlapping data sets, we kept the data with the largest population or most recent ones as recommended by Little *et al.*<sup>46</sup>. Forty three publications with redundant information were then excluded. Using standard data extraction forms, we extracted the detailed publication information, study design, characteristics of participants, gene and variant information. Subgroup information (ancestry, smoking status, or histological types) were also separately extracted from each study whenever possible. Ancestry was divided into four general groups (African, Asian, Caucasian, and other/mixed) based on ancestry of at least 80% of the subjects<sup>41</sup>. If no details of ethnicity were reported, the determination was made based on the general population of the country or region where the study was done<sup>41</sup>. When a publication reported data from multi-racial groups, data for each population were extracted and analyzed separately if possible.

To avoid the variant nomenclature confusion from different articles, we used the most current gene names and uniform identifiers ("rs" number) of variants in a public single nucleotide polymorphism (SNP) database (dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/index.html), to designate the reported variants. For articles with "rs" number, we used as it was; for these without we used bioinformatics tools such as NCBI Blast (http://www.ncbi. nlm.nih.gov/BLAST/) and UCSC In-Silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr) to find "rs" number for the reported variant; for the remaining without any "rs" number, we used the common nomenclature (eg, *MPG* Arg59Cys according to amino acid substitution and *GSTM1* present/null according to phenotype change) in the original articles.

**Statistical analysis.** All statistical analyses were performed using Stata software (version 12.0, StataCorp 2011, TX, USA), except where indicated otherwise. All tests were two-sided and considered statistically significant when p value was at 0.05 or lower, unless otherwise stated.

All variants from at least three data sources were selected for meta-analysis<sup>18</sup>. Association between a variant and lung cancer risk was assessed by study-specific crude odds ratios (ORs) and 95% confidence intervals (CIs) using a DerSimonian and Laird random-effects model<sup>47</sup>. The initial main meta-analyses assessed the variant effect using an allelic genetic model (minor allele vs. major allele) without stratification. For the variation not in the form of single nucleotide substitution, a conventional comparison from the publications was used to assess the effects (eg, *CYP2A6* [\*4 vs. non\*4], *MMP3* rs3025058 [5A vs. 6A], and *GSTM1* [null vs. present]). When average minor allele frequency (MAF) were greater than 50%, a rare occasion where major and minor alleles are flipped in different ethnic populations, we designated the minor allele from Caucasian population in all analyses. For the variant with sufficient genotype distribution data, we performed additional analyses based on dominant and recessive genetic models.

Subgroup meta-analyses were also performed by ethnicity (Caucasian and Asian), histological types (SCLC, NSCLC, AD, and SCC), and smoking status (smoking and nonsmoking), if sufficient data were available.

Between-study heterogeneity was assessed by calculating the Cochran Q statistic, with a p value less than 0.10 being the significant threshold<sup>48</sup>. We also used  $I^2$  heterogeneity metric to assess the heterogeneity<sup>49</sup>. Generally,  $I^2 < 25\%$ , 25%-50% and > 50% showed mild, moderate, and strong heterogeneity, respectively.

The publication bias of studies was evaluated by funnel plot analysis (logOR against standard error) and Begg's test<sup>50</sup>. Potential small study effect (a trend for smaller study to show larger effect) was checked by the modified Egger's test, which can lower the type I and type II error rates compared to the original Egger's test<sup>51</sup>. We also conducted an excess significance test to examine whether there was a relative excess of formally significant findings in studies due to potential sources of bias, such as selective analyses, selective outcome reporting, or fabricated data<sup>52</sup>.

For all variants that showed a significant association with lung cancer risk, we performed a sensitivity analysis to examine whether the significant summary ORs were robust after excluding the first published or first positive report, or excluding studies with controls violating Hardy-Weinberg equilibrium [HWE]. We used a Fisher's exact/chi-square to assess the HWE among controls in each dataset.

**Assessment of cumulative evidence.** For each nominally significant results from the meta-analyses, Venice criteria was used to assess the credibility of cumulative epidemiological evidence<sup>21</sup>. Venice criteria is a semi-quantitative index which assigns three aspects for the amount of evidence, extent of replication, and protection from bias, and finally generates a composite assessment of "strong", "moderate", or "weak" epidemiological credibility for an association with lung cancer risk<sup>21</sup>. For the three aspects (the amount of evidence, extent of replication, and protection, and protection from bias) of Venice criteria, each aspect was assigned three levels (A, B, or C)<sup>21</sup>. Briefly,

amount of evidence, depending on total sample size of the smallest genetic group among cases and controls in each meta-analysis, was graded as A (sample size >1000), B (sample size between 100 and 1000), or C (sample size <100). For very rare variant with frequency less than 0.5%, the amount of evidence was not assessed considering an A grade was unlikely to obtain<sup>18</sup>. The extent of replication, depending on between-study heterogeneity, was graded as A ( $I^2 < 25\%$ ), B ( $I^2$  between 25% and 50%), or C ( $I^2 > 50\%$ ). The protection from bias, considering various potential sources of bias in meta-analysis, was graded as A when there was no demonstrable bias and the bias would unlikely invalidate the association, B when there was insufficient information for identifying evidence (eg, missing information for evaluating HWE among controls in an individual study) although there was no obvious bias, and C when the bias was evident and/or was likely to explain the presence of association. More specifically, C grade was assigned if the meta-analysis had any of the following potential sources of bias: (1) the magnitude of the association was low (eg, OR < 1.15 for risk effect, OR > 0.87 for protective effect) with the exception of a highly consistent OR across studies enrolled in meta-analysis; (2) the sensitivity analysis indicated that the significant summary OR can be substantially changed; (3) the potential small study effect was present according to the modified Egger's test (p-value < 0.10); (4) an excess of significant findings was possible (excess significance test, *p*-value < 0.10; (5) there was a potential publication bias (Begg's test, *p*-value < 0.10). With the grades from three aspects, the credibility of cumulative epidemiological evidence was categorized as strong (all three aspect grades were A), moderate (any grade was B, but not C), or weak (any grade was C).

Additionally, for the non-significant associations revealed by all meta-analyses, we also evaluated the credibility of cumulative epidemiological evidence based on three aspects: the degree of heterogeneity across studies, potential bias assessment, and statistical power. The statistical power was calculated by using SNP tools<sup>53</sup>. The credibility of cumulative epidemiological evidence of non-significant association was categorized as strong (if there was no or mild [ $I^2 < 25\%$ ] heterogeneity across studies, no demonstrable bias, and sufficient statistical power [power >90%]), weak (heterogeneity  $I^2 > 50\%$ , or any potential bias detected, or low statistical power [power <80%]), or moderate (for other cases).

**Data Availability.** All data generated or analysed during this study are included in this article and its Supplementary Information file.

#### References

- Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–386, doi:10.1002/ijc.29210 (2015).
- World Health Organization & International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. Vol. 83 166-167 (IARC, 2004).
- Brownson, R. C., Alavanja, M. C., Caporaso, N., Berger, E. & Chang, J. C. Family history of cancer and risk of lung cancer in lifetime non-smokers and long-term ex-smokers. Int J Epidemiol 26, 256–263 (1997).
- Bailey-Wilson, J. E. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am. J. Hum. Genet. 75, 460–474, doi:10.1086/423857 (2004).
- 5. You, M. et al. Fine mapping of chromosome 6q23-25 region in familial lung cancer families reveals RGS17 as a likely candidate gene. *Clin. Cancer Res.* 15, 2666–2674, doi:10.1158/1078-0432.ccr-08-2335 (2009).
- Musolf, A. M. et al. Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies. Genes 8, doi:10.3390/ genes8010036 (2017).
- 7. Ku, C. S., Loy, E. Y., Pawitan, Y. & Chia, K. S. The pursuit of genome-wide association studies: where are we now&quest. J. Hum. Genet. 55, 195–206 (2010).
- 8. Wang, Y. et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet. 40, 1407–1409, doi:10.1038/ng.273 (2008).
- Broderick, P. et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 69, 6633–6641, doi:10.1158/0008-5472.can-09-0680 (2009).
- Hung, R. J. et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452, 633–637, doi:10.1038/nature06885 (2008).
- Shiraishi, K. et al. A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. Nat. Genet. 44, 900–903, doi:10.1038/ng.2353 (2012).
- 12. Wu, C. *et al.* Genetic variants on chromosome 15q25 associated with lung cancer risk in Chinese populations. *Cancer Res.* **69**, 5065–5072, doi:10.1158/0008-5472.can-09-0081 (2009).
- Yoon, K. A. et al. A genome-wide association study reveals susceptibility variants for non-small cell lung cancer in the Korean population. Hum. Mol. Genet. 19, 4948–4954, doi:10.1093/hmg/ddq421 (2010).
- Wang, M. et al. Genetic variant in DNA repair gene GTF2H4 is associated with lung cancer risk: a large-scale analysis of six published GWAS datasets in the TRICL consortium. Carcinogenesis. doi:10.1093/carcin/bgw070 (2016).
- Timofeeva, M. N. *et al.* Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. *Hum. Mol. Genet.* 21, 4980–4995, doi:10.1093/hmg/dds334 (2012).
- Brennan, P., Hainaut, P. & Boffetta, P. Genetics of lung-cancer susceptibility. Lancet Oncol 12, 399–408, doi:10.1016/s1470-2045(10)70126-1 (2011).
- Bertram, L., McQueen, M. B., Mullin, K., Blacker, D. & Tanzi, R. E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat. Genet.* 39, 17–23, doi:10.1038/ng1934 (2007).
- Zhang, B., Beeghly-Fadiel, A., Long, J. & Zheng, W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. *Lancet Oncol* 12, 477–488, doi:10.1016/s1470-2045(11)70076-6 (2011).
- Ma, X., Zhang, B. & Zheng, W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, metaanalysis, and epidemiological evidence. *Gut* 63, 326–336, doi:10.1136/gutjnl-2012-304121 (2014).
   Little, J. *et al.* The HuGENett<sup>™</sup> HuGE review handbook, version 1.0. *Ottawa, Ontario, Canada: HuGENet Canada Coordinating*
- 20. Little, J. et al. The HuGENet HuGE review handbook, version 1.0. Ottawa, Ontario, Canada: HuGENet Canada Coordinating Centre (2006).
- Ioannidis, J. P. A. *et al.* Assessment of cumulative evidence on genetic associations: interim guidelines. *International journal of epidemiology* 37, 120–132, doi:10.1093/ije/dym159 (2008).
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Grp, P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann. Intern. Med. 151, 264–W264 (2009).
- Landi, M. T. et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am. J. Hum. Genet. 85, 679–691, doi:10.1016/j.ajhg.2009.09.012 (2009).

- Hu, Z. et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat. Genet. 43, 792–796, doi:10.1038/ng.875 (2011).
- Ward, L. D. & Kellis, M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res.* 44, D877–881, doi:10.1093/nar/gkv1340 (2016).
- Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nat Methods 7, 248–249, doi:10.1038/ nmeth0410-248 (2010).
- Zienolddiny, S. & Skaug, V. Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer. Lung Cancer Targets Ther 3, 1–14 (2012).
- Lo, Y. L. et al. A polymorphism in the APE1 gene promoter is associated with lung cancer risk. Cancer Epidemiol Biomarkers Prev 18, 223–229 (2009).
- Xiao, M., Chen, L., Wu, X. & Wen, F. The association between the rs6495309 polymorphism in CHRNA3 gene and lung cancer risk in Chinese: a meta-analysis. Sci. Rep. 4, 6372, doi:10.1038/srep06372 (2014).
- Ryan, B. M. et al. Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer. Cancer Res. 75, 566–575 (2015).
- 31. Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).
- Hunt, R., Sauna, Z. E., Ambudkar, S. V., Gottesman, M. M. & Kimchi-Sarfaty, C. Silent (synonymous) SNPs: should we care about them? *Methods Mol. Biol.* 578, 23–39, doi:10.1007/978-1-60327-411-1\_2 (2009).
- Mogi, A. & Kuwano, H. TP53 mutations in nonsmall cell lung cancer. J Biomed Biotechnol 2011, 583929, doi:10.1155/2011/583929 (2011).
- Lind, H. et al. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 16, 2077–2081, doi:10.1158/1055-9965.epi-07-0153 (2007).
- Wang, J., Yu, W., Cai, Y., Ren, C. & Ittmann, M. M. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. *Neoplasia* 10, 847–856 (2008).
- Sutton, A. et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet. Genomics 15, 311–319 (2005).
- Zhang, Y. et al. Genetic polymorphisms of TERT and CLPTM1L and risk of lung cancer: A case-control study in northeast Chinese male population. Med. Oncol. 31 (2014).
- Rafnar, T. et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41, 221–227, doi:10.1038/ng.296 (2009).
- Torruella-Loran, I. et al. MicroRNA Genetic Variation: From Population Analysis to Functional Implications of Three Allele Variants Associated with Cancer. Hum. Mutat. 37, 1060–1073, doi:10.1002/humu.23045 (2016).
- Hu, Z. et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. The Journal of clinical investigation 118, 2600–2608, doi:10.1172/jci34934 (2008).
- Ioannidis, J. P., Ntzani, E. E. & Trikalinos, T. A. 'Racial' differences in genetic effects for complex diseases. Nat. Genet. 36, 1312–1318, doi:10.1038/ng1474 (2004).
- 42. Ji, Y. N., Wang, Q. & Suo, L. J. CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. *PLoS One* 7, e43397, doi:10.1371/journal.pone.0043397 (2012).
- 43. Shields, P. G. Molecular epidemiology of smoking and lung cancer. *Oncogene* **21**, 6870–6876 (2002).
- 44. Wang, J. *et al.* Method for evaluating multiple mediators: mediating effects of smoking and COPD on the association between the CHRNA5-A3 variant and lung cancer risk. *PLoS One* 7, e47705, doi:10.1371/journal.pone.0047705 (2012).
- Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008–2012 (2000).
- Little, J. *et al.* Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. *Am. J. Epidemiol.* 156, 300–310 (2002).
- 47. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177–188, doi:10.1016/0197-2456(86)90046-2 (1986).
- 48. Lau, J., Ioannidis, J. P. & Schmid, C. H. Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820–826 (1997).
- Higgins, J. P. T. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21, 1539–1558, doi:10.1002/sim.1186 (2002).
- 50. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical *research ed.*) **315**, 629-634 (1997).
- Harbord, R. M., Egge, M. & Sterne, J. A. C. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat. Med. 25, 3443–3457, doi:10.1002/sim.2380 (2006).
- 52. Ioannidis, J. P. A. & Trikalinos, T. A. An exploratory test for an excess of significant findings. *Clinical Trials* 4, 245–253, doi:10.1177/1740774507079441 (2007).
- Chen, B., Wilkening, S., Drechsel, M. & Hemminki, K. SNP\_tools: A compact tool package for analysis and conversion of genotype data for MS-Excel. *BMC Res. Notes* 2, 214, doi:10.1186/1756-0500-2-214 (2009).

### Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81171903, No. 81472190 and No. 81672316 to L. Yafei), the Chongqing Natural Science Foundation of China (No. cstc2015jcyjBX0110 to L. Yafei). The study sponsor had no role in the study design, data collection, analysis, interpretation, or writing of the report.

### **Author Contributions**

Yafei L. led the study by designing, conducting, interpreting results, writing the manuscript, and obtaining the funding; J.W., Q.L., S.Y., and W.X. coordinated the study design, literature search, data abstraction and analysis, and writing of the manuscript. Yuan L., Y.X., N.W., and L.W. coordinated literature search and data abstraction. X.M. coordinated the statistical analyses. T.C. and Y.Z. participated results interpretation and manuscript preparation. Z.S. contributed to results interpretation, discussions and manuscript preparation. All authors contributed to the final paper.

### **Additional Information**

Supplementary information accompanies this paper at doi:10.1038/s41598-017-07737-0

Competing Interests: The authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017